




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ :</p> <p>A61K 31/33, 31/34, 31/36, 31/38, 31/40, 31/41, 31/42, 31/44, 31/55, 31/155, 31/165, 31/335, 31/395, 31/415, 31/435, 31/445, C07C 279/02, 279/16, 279/18, 279/20, 279/24, C07D 203/10, 203/12, 203/14, 205/04, 207/04, 207/08, 207/09, 211/08, 211/10, 211/12, 211/14, 211/16, 211/18, 211/22, 211/26, 211/38, 211/40, 211/80, 211/82, 213/06, 213/26, 213/28, 213/30, 213/36, 213/46, 213/50, 213/53, 213/56, 213/58, 223/04, 223/08, 223/10, 231/12, 231/38, 233/60, 233/61, 271/04, 271/12, 307/78, 307/87, 307/93, 311/20, 317/44, 333/20, 333/22, 405/10, 409/10, 498/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/33460</p> <p>(43) International Publication Date: 8 July 1999 (08.07.99)</p>					
<p>(21) International Application Number: PCT/US98/25829</p> <p>(22) International Filing Date: 4 December 1998 (04.12.98)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>60/068,790</td> <td>24 December 1997 (24.12.97)</td> <td>US</td> </tr> <tr> <td>60/073,740</td> <td>5 February 1998 (05.02.98)</td> <td>US</td> </tr> </table> <p>(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).</p>	60/068,790	24 December 1997 (24.12.97)	US	60/073,740	5 February 1998 (05.02.98)	US	<p>(72) Inventors: AHMAD, Saleem; 2094 Ohadi Drive, Wall, NJ 07719 (US). WU, Shung, C.; 7121 Foxtail Court, Lawrenceville, NJ 08648 (US). ATWAL, Karnail, S.; 92 Valley View Way, Newtown, PA 18940 (US). DUGAR, Sundeeep; 749 Wingate Drive, Bridgewater, NJ 08807 (US).</p> <p>(74) Agents: RODNEY, Burton et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
60/068,790	24 December 1997 (24.12.97)	US					
60/073,740	5 February 1998 (05.02.98)	US					
<p>(54) Title: ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>(57) Abstract</p> <p>Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have structure (I) wherein n is 1 to 5; X is N or C-R⁵ wherein R⁵ is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R¹, R², R³ and R⁴ are as defined herein, and where X is N, R¹ is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.</p>							

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

ACYL GUANIDINE SODIUM/PROTON EXCHANGE
INHIBITORS AND METHOD


Field of the Invention

- 5 The present invention relates to acyl guanidine compounds which are sodium/proton exchange (NHE) inhibitors and are useful as antianginal agents and cardioprotective agents.

10 Brief Description of the Invention

In accordance with the present invention, novel acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors and have the structure I


I.



- 15 including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug ester thereof, wherein n is an integer from 1 to 5;
- wherein X is N or C-R⁵ wherein R⁵ is H, halo,
- 20 alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl;
- R¹ is H, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, (alkyl or aryl)₃Si (where each alkyl or aryl group is independent), cycloalkyl, cycloalkenyl, amino, alkylamino, alkenylamino,
- 25 alkynylamino, arylalkylamino, aryl, arylalkyl, arylamino, aryloxy, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl, heteroarylamino, heteroaryloxy, arylthio, arylsulfinyl, arylsulfonyl, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, heteroarylthio, heteroarylsulfinyl, hetero-
- 30 arylsulfonyl, halogen, haloalkyl, polyhaloalkyl such as CF₃ and CF₃CH₂, polyhaloalkyloxy such as CF₃O and CF₃CH₂O, aminothio, aminosulfinyl, aminosulfonyl, alkylsulfonyl-amino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,

- alkylaminocarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, hydroxy, acyl, carboxy,
aminocarbonyl, alkylcarbonyl, alkoxycarbonyl,
alkylcarbonyloxy, alkylcarbonylamino, arylcarbonyl,
5 arylcarbonyloxy, arylcarbonylamino, heteroarylcarbonyl,
heteroarylcarbonyloxy, heteroarylcarbonylamino, cyano,
nitro, alkenylcarbonylamino, alkynylcarbonylamino,
alkylaminocarbonylamino, alkenylaminocarbonylamino,
alkynylaminocarbonylamino, arylaminocarbonylamino,
10 heteroarylaminocarbonylamino, alkoxycarbonylamino,
alkenyloxy carbonylamino, alkynyloxy carbonylamino,
aryloxy carbonylamino, heteroaryloxy carbonylamino,
aminocarbonylamino, alkylaminocarbonyloxy, 1,1-(alkoxyl or
aryloxy)₂alkyl (where the two aryl or alkyl substituents
15 can be independently defined, or linked to one another to
form a ring, such as 1,3-dioxane or 1,3-dioxolane),
S(O)₂R⁶R⁷, -NR⁶(C=NR⁷)alkyl, -NR⁶(C=NR⁷)alkenyl,
-NR⁶(C=NR⁷)alkynyl, -NR⁶(C=NR⁷)heteroaryl, -NR⁸(C=NCN)-

amino,
$$-\text{P} \begin{array}{c} \text{O} \\ \parallel \\ \text{O} \end{array} \begin{array}{c} \text{O} \\ \diagup \\ \text{O} \end{array} \text{R}^8$$
, pyridine-N-oxide,



- $$\text{NR}^8\text{R}^9 \begin{array}{c} \text{O} \\ \parallel \\ \text{C} \end{array}$$


H₂ and n' is 0, 1, 2 or 3) or -C=CH-C-R⁸; tetrazolyl,
imidazole, oxazole or triazole; -PO(R¹³)(R¹⁴), (where R¹³
and R¹⁴ are independently alkyl, aryl, alkoxy, aryloxy,
heteroaryl, heteroarylalkyl, heteroaryloxy,
25 heteroarylalkoxy, cycloheteroalkyl, cycloheteroalkylalkyl,
cycloheteroalkoxy, or cycloheteroalkylalkoxy);

R⁶, R⁷, R⁸ and R⁹ are independently hydrogen, alkyl,
haloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl,
(cycloalkyl)alkyl or cycloheteroalkyl.

- 30 The R¹ group may have from one to five substituents,
which can be any of the R¹ groups set out above, and any of
the preferred R¹ substituents set out below.

R¹ may be substituted with the following preferred substituents: alkylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxy carbonylamino, heteroaryloxy carbonylamino, uriedo (where the uriedo nitrogens may be substituted with alkyl, aryl or heteroaryl), heterocyclylcarbonylamino (where the heterocycle is connected to the carbonyl group via a nitrogen or carbon atom), alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,

10



where J is: CHR^{23} , $\text{--}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{--}$, $\text{--}\underset{\text{R}^{24}}{\text{CH}}\text{--}\underset{\text{R}^{25}}{\text{CH}}\text{--}$ or $\text{--}\underset{\text{R}^{24}}{\text{C}}=\underset{\text{R}^{25}}{\text{C}}\text{--}$;

R²³, R²⁴ and R²⁵ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

R²⁰, R²¹, R²² are independently hydrogen, halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; and these preferred substituents may either be directly attached to R¹, or attached via an alkylene chain at an open position.


R², R³ and R⁴ are the same or different and are independently any of the groups set out for R¹ (and may be the same or different from R¹) and may optionally include one to five substituents which include any of the substituents set out for R¹.

The R², R³ and/or R⁴ groups can be attached to any of the carbons and/or to X which form the ring shown in formula I and, if desired, two of R², R³ and/or R⁴ may be attached to a single carbon atom.

The R¹, R², R³ and/or R⁴ may be joined together with the N atom and/or carbons to which they are attached to


form a non-aromatic carbocyclic ring (namely, a cycloalkyl or cycloalkenyl ring), a cycloheteroalkyl ring or a heteroaryl ring, which contains 5 to 10 ring members, preferably 5 to 7 ring members. In addition, one of R^2 , R^3 and R^4 can make a fused non-aromatic carbocyclic ring, namely a cycloalkyl ring or cycloalkenyl ring, with R^1 via linkage at the position adjacent to the linkage of X and R^1 .

The group A




10

thus may preferably include, but is not limited to, the following structures




is




Thus, the compounds of formula I of the invention can have the following structural formulae:

IA




IB



- 5 It is preferred that at least one of R¹, R², R³ and R⁴ is aryl or heteroaryl.


It is also preferred that in IB (where X is N), R¹ is aryl or heteroaryl.


- Preferred are compounds of formula I of the
 10 invention wherein n is 1, 2, 3 or 4, more preferably 1;
 preferably X is CH or N; more preferably, X is CH;
 preferably R² and R³ are independently H, lower alkyl,
 lower alkoxy, or aryl; more preferably R² and R³ are
 independently lower alkyl; and R⁴ and R⁵ are each H; and R¹
 15 is aryl or heteroaryl such as phenyl, halophenyl,
 dihalophenyl, alkylphenyl, nitrophenyl, dialkoxyphenyl,
 trifluoromethylphenyl, biphenyl, alkylthiophenyl,
 trialkoxyphenyl, halo(dialkoxy)phenyl, phenylalkyl such as
 benzyl, 2,3-dihydrobenzofuran




- Specific preferred examples of R¹ groups include
 phenyl, substituted phenyl such as 4-bromophenyl, 4-
 chlorophenyl, 3-bromophenyl, 3,5-dimethoxyphenyl, 4-
 25 methylphenyl, 2,4-dichlorophenyl, 3-nitrophenyl, 2-
 chlorophenyl, 3-chlorophenyl, 2,5-dimethylphenyl, 2-

methylphenyl, 3-methylphenyl, 4-methylphenyl, 2,3-dimethoxyphenyl, 4-trifluoromethylphenyl, 3-trifluoromethoxyphenyl, 4-biphenyl, 2-bromo-4,5-dimethoxyphenyl, 4-methylthiophenyl, 3,4,5-trimethoxyphenyl, 4-fluorophenyl, 2-chloro-3,4-dimethoxyphenyl, 4-nitrophenyl, benzyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-methoxyphenyl, 3-bromo-4-fluorophenyl, 3-ethoxyphenyl, 3-trifluoromethylphenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 3,5-ditrifluoromethylphenyl, 4-fluorophenyl, 3-trifluorophenyl, 3-(N-pyrrolyl)-phenyl, 3-(N-pyrrolidinyl)phenyl, and 3-(N-pyrazolinyl)phenyl 3-(N-imidazolyl)phenyl. Other R¹ groups include






where R₃ is NH₂, CH₃, CF₃ and R₄ and R₅ are independently H, 2-F, 2,5-diF, 2-CF₃, 3-CF₃,



5 where R₆, R₇ and R₈ are independently H, 2-nitro, 2-CF₃,



3-CF₃, 3-CN-, 5-CF₃, 4-nitro, 4-O=CH-, 2-CH₃O-,
 3-CH₃O-, 4-CH₃O-, 5-CH₃O-, 6-CH₃O-, 3-OH, 4-(CH₃)₂N-, 4-OH,
 2-F, 3-F, 4-F, 5-F, 6-F, 4-isopropyl, 2-Br, 5-Br, 3-Br, 4-
 CH₃SO₂, 4-benzyloxy, 3-CH₃CH₂-, 2-CH₃-, 3-CH₃-, 6-CH₃-, 4-t-
 10 butyl, 4-CH₃CH₂O- 4-cyclohexyl, 4-phenoxy, 4-CH₃-SO₂-NH-,
 4-isopropyl-C(=O)-NH, more preferably R¹ is dihydrobenzofuran.

In addition, in accordance with the present invention, a method for preventing, inhibiting or treating
 angina (stable or unstable), cardiac dysfunction,
 15 myocardial necrosis, and arrhythmia is provided, wherein a compound of formula I is administered in a therapeutically effective amount which inhibits sodium/proton exchange.

Detailed Description of the Invention


20 The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances.

Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as employed herein alone or as part of
 25 another group includes both straight and branched chain hydrocarbons, containing 1 to 40 carbons, preferably 1 to

20 carbons, more preferably 1 to 12 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various additional branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents which may be any of the R^1 or the R^1 substituents set out herein.

Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 4 to 12 carbons, forming the ring and which may be fused to one aromatic ring as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,

20



any of which groups may be optionally substituted with 1 to 4 substituents which may be any of the R^1 groups, or the R^1 substituents set out herein.

25 The term "cycloalkenyl" as employed herein alone or as part of another group refers to cyclic hydrocarbons containing 5 to 20 carbons, preferably 6 to 12 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.

30 The term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl)

and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings) and may be optionally substituted through available carbon

5 atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy,

10 arylthio, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, aryl or any of the other aryl compounds mentioned in the definitions), thiol,

15 alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl,

20 arylsulfinylalkyl, arylsulfonylamino or arylsulfonaminocarbonyl or any of the R¹ groups or the R¹ substituents set out herein.

The term "aralkyl", "aryl-alkyl" or "aryllower alkyl" as used herein alone or as part of another group

25 refers to alkyl groups as discussed above having an aryl substituent, such as benzyl, or phenethyl, or naphthylpropyl, or an aryl as defined above.

The term "lower alkoxy", "alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as part of another

30 group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.

The term "amino" as employed herein alone or as part of another group may optionally be independently substituted with one or two substituents, which may be the

35 same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl,

haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. These substituents may be further substituted with a carboxylic acid or any of the R¹ groups or R¹ substituents thereof as set out above. In addition, the amino substituents may be
5 taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl,
10 or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy.

The term "lower alkylthio", alkylthio, "arylthio" or "aralkylthio" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or
15 aryl groups linked to a sulfur atom.

The term "lower alkylamino", "alkylamino", "arylamino", or "arylalkylamino" as employed herein alone or as part of another group includes any of the above alkyl, aryl or arylalkyl groups linked to a nitrogen atom.

20 The term "acyl" as employed herein by itself or part of another group, as defined herein, refers to an organic radical linked to a carbonyl $\left(\begin{smallmatrix} \text{O} \\ \parallel \\ \text{C} \end{smallmatrix} \right)$ group; examples of acyl groups include any of the R¹ groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cycloheteroalkanoyl and the
25 like.

The term "alkanoyl" as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.

30 Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 3 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to
35 six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-

octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, alkylthio or any of the R¹ groups, or the R¹ substituents set out herein.

Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, or any of the R¹ groups, or the R¹ substituents set out herein.












Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may optionally be substituted as defined above for "alkyl".


Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted as defined above for "alkenyl" and "alkynyl".

Suitable alkylene, alkenylene or alkynylene groups (CH₂)_p (where p is 1 to 8, preferably 1 to 5) (which may include alkylene, alkenylene or alkynylene groups) as

defined herein, may optionally include 1, 2, or 3 substituents which include any of the R¹ groups, or the R¹ substituents set out herein.

Examples of alkylene, alkenylene and alkynylene
5 include






The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF_3 , with chlorine or fluorine being preferred.

The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.


The term "cycloheteroalkyl" as used herein alone or as part of another group refers to a 5-, 6- or 7-membered saturated or partially unsaturated ring which includes 1 to 2 hetero atoms such as nitrogen, oxygen and/or sulfur, linked through a carbon atom or a heteroatom, where possible, optionally via the linker $(\text{CH}_2)_p$ (which is defined above), such as



and the like. The above groups may include 1 to 4 substituents such as alkyl, halo, oxo and/or any of of the R^1 groups, or the R^1 substituents set out herein. In addition, any of the above rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

The term "heteroaryl" as used herein alone or as part of another group refers to a 5- or 6- membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such

as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), and includes possible N-oxides. The heteroaryl group may optionally include 1 to 4 substituents such as any of the R^1 groups or the R^1 substituents set out above. Examples of heteroaryl groups include the following:



and the like.

The term "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to a $(CH_2)_p$ chain.

The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers to a

heteroaryl group as defined above linked through a C atom or heteroatom to a $-(CH_2)_p-$ chain, alkylene or alkenylene as defined above.

The term "polyhaloalkyl" as used herein refers to an
5 "alkyl" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF_3CH_2 , CF_3 or $CF_3CF_2CH_2$.

The term "polyhaloalkyloxy" as used herein refers to
an "alkoxy" or "alkyloxy" group as defined above which
10 includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF_3CH_2O , CF_3O or $CF_3CF_2CH_2O$.

The compounds of formula I can be present as salts, in particular pharmaceutically acceptable salts. If the
15 compounds of formula I have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids,
20 such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as
25 hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C_1-C_4) -alkyl- or aryl-sulfonic acids which are
30 unsubstituted or substituted, for example by halogen, for example methane- or p-toluene-sulfonic acid. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. The compounds of formula I having at least one acid group (for example COOH)
35 can also form salts with bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium

or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-,
5 triethyl-, tributyl- or dimethyl-propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example,
10 for the isolation or purification of free compounds I or their pharmaceutically acceptable salts, are also included.

Preferred salts of the compounds of formula I include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate, nitrate or maleate.

15 All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one of the R substituents.
20 Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric or enantiomeric products
25 are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.

It should be understood that the present invention includes prodrug forms of the compounds of formula I such as alkylesters of acids or any of the prodrugs for
30 guanidines disclosed in U.S. Application Serial No. 08/641,718, filed May 2, 1996, and in U.S. Patent No. 5,561,146 which are incorporated herein by reference.


The compounds of the instant invention may, for example, be in the free or hydrate form, and may be
35 obtained by methods exemplified by the following descriptions.

The compounds of formula I may be prepared by the preferred processes described in the following reaction schemes. Exemplary reagents and procedures for these reactions appear hereinafter and in the working Examples.

- 5 Compounds of formula I of the invention can be prepared from the corresponding carboxylic acids by using the sequence of steps outlined in Scheme 1 set out below. Activation of carboxylic acid 1 with various activating reagents (e.g. 1,1'-carbonyldiimidazole (CDI), thionyl chloride, oxalyl chloride, and the like) (employing a molar ratio of activating agent:acid 1 within the range from about 1:1 to about 10:1) in an organic solvent such as THF or methylene chloride, convert acids 1 to 2. Subsequent treatment of compounds of formula 2 with guanidine in DMF or THF (employing a molar ratio of guanidine:2 within the range from about 1:1 to about 20:1) gives compounds of the formula I.

- The carboxylic acids of formula 1 can either be commercially available or they can be prepared by methods known in the art.

Scheme 1




- 25 (L = a leaving group such as halide, alkoxy, aryloxy or imidazolyl).

- Compounds of formula IA of the invention where n=1 and X is other than nitrogen (e.g., arylcyclopropane-carboxyl guanidines) can also be prepared from the corresponding α,β -unsaturated carboxylic acids or esters by using the sequence of steps outlined in Scheme 2 (employing a molar ratio of CH_2N_2 :3 within the range from about 1:1 to

about 20:1, and a molar ratio of guanidine:4 within the range from about 1:1 to about 20:1.

Scheme 2


5



R¹⁰ = H, Me, Et, Pr, Bu, etc.

The acids or esters 3 used in this preparation are either commercially available or they can be prepared by methods known in the art. For example, 3-aryl-propenoic acids (6, R¹ = aryl) can be prepared as outlined below. Condensation of malonic acid with the aldehydes in solvents such as pyridine with catalysts such as piperidine or pyrrolidine, gives the corresponding 4-aryl-propenoic acids. The starting aldehydes are either commercially available or they can be prepared by methods well known to those skilled in the art.

20




The compounds of formula IB of the invention where X is nitrogen can be prepared as in Scheme 3. Compound of formula 8 wherein L is a leaving group (halide, triflate, etc.) is treated with an amine of formula 7 (employing a molar ratio of 8:7 within the range from about 20:1 to about 1:20) in the presence of a base (e.g., triethylamine, and ethyldiiso-propylamine) in an organic solvent (such as DMSO) to provide a compound of formula 9. Compound 9 is

converted to the desired product IB by deprotection of the acid under appropriate conditions followed by coupling of the resulting acid 10 with guanidine (employing a molar ratio of guanidine:10 within the range from about 1:1 to about 20:1) utilizing a coupling agent such as 1,1'-carbonyldi-imidazole. The coupling of 7 and 8 to provide compounds of formula 9 can also be carried out in the presence of palladium catalysts by methods described in the literature (Wagaw, S. et al, J. Amer. Chem. Soc. 1997, Vol. 119, 8458 and references therein).


Compounds of formulae 7 and 8 are commercially available or they can be prepared by methods described in the literature.

15 Scheme 3




Compounds of formula IC of the invention wherein two of R², R³ and R⁴ taken together form a carbocyclic ring can be prepared according to Scheme 4. The reaction of cyclopentadiene 11 with an unsaturated ester of formula 12 in the presence of a Lewis acid (diethylaluminum chloride, tin chloride etc.) gives compound of formula 13 which can be converted to the desired compounds of formula 1C by reacting with guanidine as described in Scheme 2. Compounds of formula 11 and 12 are commercially available or they can be prepared by methods described in the literature.

Scheme 4




- 5 Compounds of formula IA of the invention wherein $n = 1$ and X is other than nitrogen (e.g., arylcyclopropane-carboxy guanidines) can also be prepared according to Scheme 5. An olefin of formula 14 is reacted with ethyl diazoacetate (15) in the presence of a transition metal catalyst such as rhodium acetate, palladium acetate etc. to provide compounds of formula 16. Condensation of 16 with guanidine provides compounds of formula IA. Compounds of formulas 14 and 15 are commercially available or they can be prepared by standard methods described in the literature.

Scheme 5



20

Scheme 6



As set forth in Scheme 6, the process for the preparation of 2-(2',3'-dihydrobenzofuran-4'-yl)cyclopropane carboxylate (used as starting materials) involves the above chemical reactions.

The preparation of iminium salt 19 from olefin 17 and N,N-disubstituted ketene iminium salt 18 is carried out in a suitable solvent or solvent mixtures such as hydrocarbons, halogenated hydrocarbons, ethers, esters, ketones, amides and nitriles. The preferred solvent is dichloromethane. N,N-disubstituted ketene iminium salt 18 may be generated in situ by the reaction of an N,N-disubstituted amide with an acylating reagent such as acyl halides or anhydrides in the presence of a base choosing from aromatic or aliphatic bases. The preferred acylation reagent is trifluoromethanesulfonic anhydride and the preferred base is collidine. The N,N-disubstituted ketene iminium salt 18 may alternatively be generated in situ from an α -halo-N,N-disubstituted enamine such as α -chloro-N,N-disubstituted enamine with a Lewis acid such as zinc chloride. The reaction temperatures range from 0-150°C, with 30-100°C being preferred. The preferred starting material is 4-vinyl-2,3-dihydrobenzofuran and the preferred

ketene iminium salt precursors are N,N-dimethylacetamide and N,N-dimethylisobutyramide.

The preparation of cyclobutanone 20 from the corresponding iminium salt 19 by hydrolysis under aqueous conditions is carried out with the optional use of acid such as HCl or other conventional acid.

The preparation of acid 21 is carried out by generating the enolate of 20 using a base in a suitable solvent or solvent mixture followed by halogenation with a halogenating reagent to form the corresponding α -haloketone. The base used in this step includes LiHMDS, NaHMDS, KHMDS or any other base capable of enolyzing cyclobutanones. The preferred base is LiHMDS. A suitable solvent or solvent mixture includes ethers, hydrocarbons, or amides with the preferred solvent being THF. The temperature for the enolate formation may range from -110° to 50°C with -80° to 25°C being preferred. The halogenating reagent includes N-bromosuccinimide (NBS), N-chlorosuccinimide (NCS), N-iodosuccinimide (NIS), bromine, chlorine, iodine, dihalohydantoin or other electrophilic halogenating reagents with NBS being preferred.


Subsequent treatment of the α -haloketone with a base in a suitable solvent or solvent mixture forms 21. The base used in this step includes metal hydroxide or alkoxide or aryloxide with metal hydroxide such as sodium hydroxide being preferred. The suitable solvent or solvent mixture may be any conventional solvent with the mixture of THF and water being preferred. The reaction temperature may range from -80° to 60°C with -20° to 40°C being preferred.

The resolution of 21 to form 21a is carried out by reaction of 21 with an appropriate chiral amine in a suitable solvent or solvent mixture to form the corresponding amine salt. The chiral amine includes conventional amines for resolution purpose with (R)-1-phenylethylamine preferred. The solvent or solvent mixture includes any conventional solvent with ethanol preferred.

The temperature may range from 160° to -20°C with 80° to 0°C preferred.

The amine salt is converted to free acid 21a by reaction with aqueous acid in a suitable solvent or solvent mixture. The aqueous acid includes those acids that are stronger than the carboxylic acid 21 with aqueous HCl being preferred. A suitable solvent includes any conventional solvent with ethyl acetate being preferred. The acid 21a can be converted to compound IA of the invention by coupling 21a with guanidine in the presence of a coupling agent such as carbonyl diimidazole.

Scheme 7




15 R^{11} = Aryl, lower alkyl, benzyl

R^{12} = Aryl, lower alkyl, benzyl, arylcarbonyl, alkylcarbonyl, formyl, alkylaminocarbonyl, arylaminocarbonyl

20 Compounds of formula ID of the invention can be prepared as in Scheme 7. The reaction of unsaturated ester 3 with N-substituted glycine and paraformaldehyde gives compound of formula 24 which can be converted to the desired compound of formula ID of the invention by reacting with guanidine as described in Scheme 2.


Scheme 8



R⁷ and R⁸ = lower alkyl, alkoxy or can be joined to form a cycloalkyl forming a 5,6 or 7 membered ring

Compounds of formula IA of the invention can also be prepared as shown in Scheme 8. The reaction of an unsaturated ester such as 3 with an ylid such as 26 gives 27 which can be hydrolyzed to the corresponding acid and coupled with guanidine using an appropriate coupling reagent such as carbonyl diimidazole to give IA.


Scheme 9



R⁷ and R⁸ = lower alkyl or can be joined to form a cycloalkyl forming a 5,6 or 7 membered ring

Compounds of formula IA of the invention can also be prepared as shown in Scheme 9. The reaction of an unsaturated ester such as 27 with compounds of type 29 gives 30 which can be decarboxylated to the corresponding acid 31 and coupled with guanidine using an appropriate coupling reagent such as carbonyl diimidazole to give IA.


Scheme 10



5 Compounds of formula IE of the invention can be prepared as shown in Scheme 10. The reaction of 32 with an appropriate carboxylic acid using an appropriate coupling reagent such as PyBOP followed by treatment with guanidine in an appropriate solvent such as DMF gives IE.

10

Scheme 11



15 Compounds of formula IF of the invention can be prepared as shown in Scheme 11. The reaction of 34 with an appropriate alkylating agent in the presence of an appropriate base such as triethylamine followed by treatment with guanidine in an appropriate solvent such as
20 DMF gives IF.

The above schemes as shown fix the position of the acyl guanidine moiety relative to the group B. However, it will be appreciated that these schemes apply to preparing compounds of formula I of the invention wherein the acyl
25 guanidine moiety may be attached at any of the ring positions of the group A.

The compounds of formula I of the invention exhibit Na⁺/H⁺ exchange inhibitory activity, and hence, are useful for treating or preventing disorders caused by
30 intracellular acidosis during myocardial ischemia, such as cardiac dysfunction, myocardial necrosis, arrhythmia, reperfusion injury, and the like which are observed in

ischemic heart diseases (e.g., myocardial infarction and angina pectoris).

Thus, compounds of formula I of the invention may be used as antiischemic agents, i.e., for the treatment of
5 ischemic conditions such as myocardial ischemia, cerebral ischemia, lower limb ischemia and the like. Thus, a composition containing one (or a combination) of the compounds of this invention, may be administered to a species of mammal (e.g., humans, dogs or cats) suffering
10 from an ischemic condition.

A single dose, or two to four divided daily doses, provided on a basis of about 0.001 to about 100 mg per kilogram of body weight per day, preferably about 0.1 to about 25 mg per kilogram of body weight per day is
15 appropriate. The substance is preferably administered orally, but parenteral routes such as the subcutaneous, intramuscular, intravenous or intraperitoneal routes or any other suitable delivery system, such as intranasal or transdermal routes can also be employed.

20 As a result of the Na^+/H^+ exchange inhibiting activity of the compounds of this invention, these compounds are also useful in the treatment of cardiovascular disorders. For example, compounds of the present invention are useful as therapy for congestive
25 heart failure, therapy for peripheral vascular disorders (e.g. Raynaud's Disease), therapy for hypertension, as anti-anginal agents, as antifibrillatory agents, and in limiting myocardial infarction.

Compounds of the present invention are additionally
30 expected to be useful in the treatment of cerebral ischemia (e.g., stroke).

As a result of the Na/H exchange inhibiting activity, the compounds of this invention can also be used for the treatment of diseases associated with proliferation
35 of smooth muscle cells, mesangial cells, and fibroblasts. Such diseases include restenosis after angioplasty, renal fibrosis, atherosclerosis, hepatic fibrosis, prostate

hypertrophy, pulmonary fibrosis and glomerular nephrosclerosis.

Other uses for compounds of this invention which inhibit Na/H exchange include treatments for diseases such as cardiac hypertrophy, ischemic/reperfusion injury associated with organ transplantation, and other surgical procedures such as percutaneous transluminal coronary angioplasty (PTCA).

Due to their Na/H exchange inhibiting properties, compounds of this invention can also be used for CNS disorders associated with cerebral ischemia such as cerebral infarction, cerebral edema and like. Additionally, they can be used for ischemia and ischemia-reperfusion injury resulting from shock and trauma.

The compounds of the invention are also anti-thrombotic agents and antiproliferative agents and are also useful in treating renal disease.

The compounds of the invention are also dual inhibitors of NHE-1 and NHE-3 and thus can be used as cardioprotectants for the treatment of heart disease, whilst also improving renal function by protecting against renal damage, or reversing hypertension by a direct modulation of sodium resorption in the kidney. As dual inhibitors, the compounds of the invention are also useful in a combination of therapies, for example, hypertension in patients with acute coronary syndromes, MI, recovery from MI and chronic stable angina. They are also useful for heart failure when an anti-hypertensive or diuretic agent is required for treatment.

Compounds of this invention can be additionally used for the treatment of diabetes mellitus and other diabetic complications and for lowering serum lipids such as lowering LDL-cholesterol.

The compounds of this invention can also be formulated in combination with a diuretic such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide,


methchlorthiazide, trichloromethiazide, polythiazide or benzthiazide as well as ethacrynic acid, tricyclic, chlorthalidone, furosemide, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds, angiotensin converting enzyme inhibitors such as captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazapril, delapril, pentopril, quinapril, ramipril, lisinopril, and salts of such compounds, thrombolytic agents such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC, Eminase, Beecham Laboratories), or calcium channel blocking agents such as verapamil, nifedipine or diltiazem. Such combination products if formulated as a fixed dose employ the compounds of this invention within the dose range described above and the other pharmaceutically active agent within its approved dose range.

The compounds of formula I, and combinations thereof, can be formulated, as described above, in compositions such as tablets, capsules or elixirs for oral administration, in sterile solutions or suspensions for parenteral administration, and may also be administered via transdermal patch or nasal inhalation solutions. About 10 to about 500 milligrams of a compound of formula I is compounded with physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.

The following examples and preparations describe the manner and process of making and using the invention and are of preferred embodiments of the invention. It should be understood that there may be other embodiments which fall within the spirit and scope of the invention as defined by the claims appended hereto.


Example 1

trans-N-(Aminoiminomethyl)-2-(4-methylphenyl)cyclopropane-
carboxamide




5

A.



To a solution of trans-4-methylcinnamic acid



10

(81 mg, 0.5 mmol) in THF (10 mL) was added Pd(OAc)₂ (5 mg) in small portions followed by a cold (0°C) ethereal diazomethane (CH₂N₂) solution [6 mL, prepared from 1,1-methyl-3-nitro-1-nitrosoguanidine (74 mg, 4.5 mmol)] with continuous stirring during 10-15 minutes.

15

The addition of the diazomethane was done dropwise at 0°C just following each addition of the palladium catalyst. A few drops of glacial acetic acid were added at the conclusion of the reaction to quench any unreactive diazomethane. The reaction mixture was filtered through a


20

Celite bed and the cake was washed with fresh THF (2 x 10 mL). The filtrate was concentrated to give the title compound in the form of a dark oil (86 mg, 90% yield).

25

¹H NMR (270 MHz, CDCl₃) δ 7.08 (d, J=8.03 Hz, 2H); 6.98 (d, J=8.32 Hz, 2H); 3.70 (s, 3H); 2.5-2.45 (m, 1H); 2.30 (s, 3H); 1.85-1.84 (m, 1H); 1.60-1.55 (m, 1H); 1.32-1.25 (m, 1H).

B.




To a stirring solution of guanidine (148 mg, 2.5
 5 mmol in DMF (1 mL) was added a solution of Part A compound
 in DMF (0.5 mL). Stirring was continued for 3 h at room
 temperature. Addition of water (2 mL) and extraction with
 ethyl acetate (2 x 5 mL), followed by evaporation of
 solvent afforded the crude product as a tan solid. The
 10 title compound was isolated as a TFA salt (white solid, 95
 mg, 75% overall yield) from the preparative HPLC.



[Analytical HPLC: ret. time = 2.83 min; 100% purity; LC/MS-
 m/e (M+H)+218+; ¹H NMR (270 MHz; CD₃OD) δ 7.1 (d, J=8.2 Hz,
 15 2H); 7.04 (d, J=8.2 Hz, 2H); 2.62-2.52 (m, 1H); 2.29 (s,
 3H); 2.06-1.95 (m, 1H); 1.74-1.65 (m, 1H); 1.57-1.49 (m,
 1H)].

Example 2

20 trans-N-(Aminoiminomethyl)-2-(2,3-dihydro-4-benzofuranyl)-
cyclopropanecarboxamide



25 A. 2,3-Dihydrobenzofuran-4-carboxylic acid




Benzofuran-4-carboxylic acid

[Eissenstat, et al, J. Medicinal Chemistry, 38 (16) 3094-
 30 3105 (1995)] (10.0 g, 61.7 mmol) was hydrogenated (60 psi)

in acetic acid (100 mL) over 10% Pd/C (2 g) for 12 hr. The mixture was filtered and the filtrate was diluted with water (500 mL) to give 2,3-dihydrobenzofuran-4-carboxylic acid as a white powder (8.4 g, 83%). A sample was
5 recrystallized from isopropanol to give fine white needles (mp: 185.5-185.5°C).

B. 2,3-Dihydrobenzofuran-4-methanol




10

A solution of Part A 2,3-dihydrobenzofuran-4-carboxylic acid (10 g, 61 mmol) in THF (100 mL) was stirred as LAH (4.64 g, 122 mmol) was slowly added. The mixture was heated to reflux for 30 min. The mixture was cooled
15 and quenched cautiously with ethyl acetate and then with 1N HCl (150 mL). The mixture was then made acidic with 12N HCl until all the inorganic precipitate dissolved. The organic layer was separated, and the inorganic layer was extracted twice with ethyl acetate. The organic layers
20 were combined, washed twice with brine, and then concentrated in vacuo. This oil was distilled to give 2,3-dihydrobenzofuran-4-methanol as a clear oil that crystallized upon cooling (8.53 g, 87.6%).

25

C. 2,3-Dihydrobenzofuran-4-carboxaldehyde




30

DMSO (8.10 mL, 114 mmol) was added at -78°C to a stirred solution of oxalyl chloride in CH₂Cl₂ (40 mL of a 2M solution). A solution of Part B 2,3-dihydrobenzofuran-4-methanol (8.53 g, 56.9 mmol) in CH₂Cl₂ (35 mL) was added dropwise, and the solution stirred at -78°C for 30 min. Triethylamine (33 mL, 228 mmol) was added cautiously to quench the reaction. The resulting suspension was stirred

at room temperature for 30 min. and diluted with CH_2Cl_2 (100 mL). The organic layer was washed three times with water, and twice with brine, and then concentrated in vacuo to give 2,3-dihydrobenzofuran-4-carboxaldehyde as an oil
 5 (8.42 g, 100%) that was used without purification.

D. trans-3-(2,3-Dihydro-4-benzofuranyl)-2-propenoic acid




10

A solution of 2,3-dihydrobenzofuran-4-carboxaldehyde (8.42 g, 56.9 mmol) and malonic acid (11.86 g, 114 mmol) in pyridine (30 mL) and pyrrolidine (1 mL) was heated at
 15 reflux for 6 hr. The solution was cooled and poured into cold water (400 mL). The mixture was made strongly acidic with 12 N HCl to give a pale yellow precipitate that was filtered and air dried. The pale yellow powder was recrystallized from isopropanol to give white flakes (10.3
 20 g, 95.3%, mp: 205-207°C).

Anal. for $\text{C}_{11}\text{H}_{10}\text{O}_3$: Calc'd, C, 69.46; H, 5.30. Found, C, 69.36; H, 5.17.


25 ^1H NMR (300 MHz, CDCl_3) δ 7.76 (d, 1H, $J=16.1$ Hz), 7.15 (t, 1H, $J=7.8$ Hz), 7.07 (d, 1H, $J=7.8$ Hz), 6.81 (d, 1H, $J=7.8$ Hz), 6.37 (d, 1H, $J=16.1$ Hz), 4.62 (t, 2H, $J=8.8$ Hz), 3.33 (t, 2H, $J=8.8$ Hz).

30 E. trans-2-(2,3-Dihydro-4-benzofuranyl)-cyclopropanecarboxylic acid, methyl ester



The title compound was prepared from title D compound by the same procedure as described in Example 1, Part A.


- 5 F. trans-N-(Aminoiminomethyl)-2-(2,3-dihydro-4-benzofuranyl)-cyclopropanecarboxamide



- 10 The title compound was prepared from the title E compound by the same procedure as described in Example 1, Part B.

Example 3


- 15 (1S-trans)-N-(Aminoiminomethyl)-2-(2,3-dihydro-4-benzofuranyl)cyclopropanecarboxamide



- 20 The title compound was prepared from the title compound of Example 2 (racemic mixture) by HPLC using Chiralpak-AD column with isopropanol:hexanes: triethylamine (10:90:0.2) as a mobile phase.

- 25 Example 4

(1R-trans)-N-(Aminoiminomethyl)-2-(2,3-dihydro-4-benzofuranyl)cyclopropanecarboxamide



30







The title compound was prepared from the title compound of Example 2 (racemic mixture) by HPLC using Chiralpak-AD column and isopropanol:hexanes: triethylamine (10:90:0.2) as a mobile phase.









5










Examples 5 to 48










The following compounds were prepared from the corresponding α,β -unsaturated acids or esters by the method described in Examples 1 and 2.










10





Example	Structure	Characterization (MS)
5		(M+H) ⁺ 246
6		(M+H) ⁺ 246
7		(M+H) ⁺ 282
8		(M+H) ⁺ 237
9		(M+H) ⁺ 203
10		(M+H) ⁺ 282

Example No.	Structure	Characterization (MS)
11		(M+H) ⁺ 264
12		(M+H) ⁺ 362
13		(M+H) ⁺ 218
14		(M+H) ⁺ 272
15		(M+H) ⁺ 249
16		(M+H) ⁺ 238
17		(M+H) ⁺ 264
18		(M+H) ⁺ 272

Example No.	Structure	Characterization (MS)
19		(M+H) ⁺ 288
20		(M+H) ⁺ 280
21		(M+H) ⁺ 342
22		(M+H) ⁺ 248
23		(M+H) ⁺ 250
24		(M+H) ⁺ 294
25		(M+H) ⁺ 222
26		(M+H) ⁺ 298
27		(M+H) ⁺ 249


28		(M+H) ⁺ 294
29		(M+H) ⁺ 234
30		(M+H) ⁺ 220
31		(M+H) ⁺ 250
32		(M+H) ⁺ 247
33		(M+H) ⁺ 220
34		(M+H) ⁺ 250
35		(M+H) ⁺ 240
36		(M+H) ⁺ 240

37		(M+H) ⁺ 240
38		(M+H) ⁺ 240
39		(M+H) ⁺ 246
40		(M+H) ⁺ 264
41		(M+H) ⁺ 313
42		(M+H) ⁺ 301
43		(M+H) ⁺ 301
44		(M+H) ⁺ 282
45		(M+H) ⁺ 264

46		(M+H) ⁺ 340
47		(M+H) ⁺ 234
48		(M+H) ⁺ 248
49		(M+H) ⁺ 246

Example 50

trans-N-(Aminoiminomethyl)-2-(2,5-dimethylphenyl)cyclopropanecarboxamide




5

To a stirred solution of ethyl diazoacetate (0.105 mL, 1.0 mmol) and 2,5-dimethylstyrene (198 mg, 1.5 mmol) in 2 mL methylene chloride at -78°C was added Pd(OAc)₂ (10 mg) and the reaction mixture was gradually allowed to come to RT over approximately 10 minutes. The mixture was concentrated to remove solvent and the resulting residue was treated with a solution of guanidine (295 mg, 5 mmol) in 2 mL DMF. The mixture was stirred at RT for 3h and concentrated. The resulting crude brownish residue was shaken with 5 mL ethyl acetate to extract the soluble material and the ethyl acetate solution was added to a prepacked Varian Chem Elut™ 5 mL column, pretreated with 3 mL water. An additional 5 mL ethyl acetate was used to

extract the column and the combined ethyl acetate eluate was concentrated. The residue was subjected to preparative HPLC (C18 column/90:10:0.1 to 10:90: 0.1 water-MeOH-TFA gradient) providing 13 mg of the title compound (as a trifluoroacetic acid salt), LRMS (M+H)⁺ = 232.

Examples 50A and 50B

















The Examples 49A and 49B compounds are prepared by resolving the racemic mixture from Example 49 by chiral chromatography (Chirapak AD column/hexanes-IPA-triethylamine 90:10:0.2). The title compound is eluted as the faster moving enantiomer, $[\alpha]_D^{+218^\circ\text{C}} = 1$ (MeOH).


Examples 51-67

The following compounds were prepared from the corresponding olefins using the procedure described above for Example 50.


Example No.	Structure	Characterization (MS)
51		(M+H) ⁺ 216
52		(M+H) ⁺ 286
53		(M+H) ⁺ 296

54		(M+H) ⁺ 252 ⁺
55		(M+H) ⁺ 234
56		(M+H) ⁺ 232
57		(M+H) ⁺ 222
58		(M+H) ⁺ 222
59		(M+H) ⁺ 248
60		(M+H) ⁺ 218
61		(M+H) ⁺ 218
62		(M+H) ⁺ 234
63		(M+H) ⁺ 246

64		(M+H) ⁺ 264
65		(M+H) ⁺ 340
66		(M+H) ⁺ 272
67		(M+H) ⁺ 272


Example 68

5 A.



To a solution of ethyl 4-nitrocinnamate (0.5 g, 2.2 mmol) and cyclopentadiene (0.17 g, 2.7 mmol) in toluene (20 mL) was added 1M solution of diethylaluminum chloride (2.6 mL, 2.6 mmol) in hexane at -78°C. The resulting solution was stirred at -78°C for 1.5 h and warmed to ambient temperature and stirred for 12 h. The solution was washed with 1N NaOH solution, dried (MgSO₄) and concentrated. The residue was chromatographed on silica gel (ethyl acetate:hexanes/ 1:4) to give the desired product (0.39 g) as a 4:1 mixture of 2 isomers.

B.



















To a solution of title A compound (0.20 g, 0.7 mmol) in DMF (5 mL) was added guanidine (0.2 g, 3.5 mmol) at ambient temperature. The resulting solution was stirred for 16 h at ambient temperature. The solution was diluted with ethyl acetate and washed with brine. The organic layer was dried (MgSO_4) and concentrated. The residue was purified by reverse phase preparative HPLC to give the desired product as a white solid. $(\text{M}+\text{H})^+ = 301$.









Example 69-113









Using the procedure described in Example 68, the following compounds were prepared.









Examples	Structure	Characterization MS
69 isomer A		$(\text{M}+\text{H})^+ 274$
70 isomer B		$(\text{M}+\text{H})^+ 274$
71		$(\text{M}+\text{H})^+ 290$
72		$(\text{M}+\text{H})^+ 301$


73		(M+H) ⁺ 291
74		(M+H) ⁺ 274
75		(M+H) ⁺ 274
76		(M+H) ⁺ 335
77		(M+H) ⁺ 335
78		(M+H) ⁺ 298
79		(M+H) ⁺ 335
80		(M+H) ⁺ 335


81		(M+H) ⁺ 284
82		(M+H) ⁺ 291
83		(M+H) ⁺ 291
84		(M+H) ⁺ 286
85		(M+H) ⁺ 286
86		(M+H) ⁺ 286
87		(M+H) ⁺ 286
88		(M+H) ⁺ 291

89		(M+H) ⁺ 291
90		(M+H) ⁺ 286
91		(M+H) ⁺ 286
92		(M+H) ⁺ 270
93		(M+H) ⁺ 270
94		(M+H) ⁺ 270
95		(M+H) ⁺ 270
96		(M+H) ⁺ 270

97		(M+H) ⁺ 270
98		(M+H) ⁺ 353
99		(M+H) ⁺ 353
100		(M+H) ⁺ 300
101		(M+H) ⁺ 274
102		(M+H) ⁺ 324
103		(M+H) ⁺ 340
104		(M+H) ⁺ 292

105		(M+H) ⁺ 325
106		(M+H) ⁺ 392
107		(M+H) ⁺ 342
108		(M+H) ⁺ 309
109		(M+H) ⁺ 313
110		(M+H) ⁺ 375
111		(M+H) ⁺ 321
112		(M+H) ⁺ 367



113		(M+H) ⁺ 351
-----	---	------------------------









Example 114









- 5 To a solution of the compound of Example 96 in methanol (20 mL) was added carbon on platinum. The resulting mixture was stirred at ambient temperature and ambient pressure of hydrogen for 4 hr and filtered. The filtrate was concentrated the residue was purified by
- 10 reverse phase preparative HPLC to give the title product as a white powder (M+H)⁺=272.









Examples 115 to 145






- Following the procedure of Examples 68 and 114, the
- 15 following compounds were prepared.

<u>Example</u>	<u>Structure</u>	<u>MW</u>
115		(M+H) ⁺ 272
116		(M+H) ⁺ 272


117		(M+H) ⁺ 272
118		(M+H) ⁺ 258
119		(M+H) ⁺ 258
120		(M+H) ⁺ 288
121		(M+H) ⁺ 300
122		(M+H) ⁺ 286
123		(M+H) ⁺ 288
124		(M+H) ⁺ 288

125		(M+H) ⁺ 288
126		(M+H) ⁺ 288
127		(M+H) ⁺ 288
128		(M+H) ⁺ 293
129		(M+H) ⁺ 302
130		(M+H) ⁺ 342
131		(M+H) ⁺ 355
132		(M+H) ⁺ 276


133		(M+H) ⁺ 326
134		(M+H) ⁺ 294
135		(M+H) ⁺ 293
136		(M+H) ⁺ 327
137		(M+H) ⁺ 337
138		(M+H) ⁺ 394
139		(M+H) ⁺ 344
140		(M+H) ⁺ 311

141		(M+H) ⁺ 315
142		(M+H) ⁺ 377
143		(M+H) ⁺ 323
145		(M+H) ⁺ 327
145A		(M+H) ⁺ 353

Example 146



A.




5

To a solution of *tert*-butyldiethylphosphonoacetate (6.94g, 27.5 mmol) in THF (50 ml) at 0°C was added slowly sodium hexamethyldisilazide (NaHMDS) (27.5 ml, 27.5 mmol).


The resulting solution was warmed to 25°C and stirred 30 minutes. After cooling the reaction mixture to 0°C, a solution of 3,5-dichlorobenzaldehyde (4.38g, 25 mmol) in THF (25 ml) was slowly added. The reaction mixture was warmed to 25°C and stirred overnight. The reaction mixture was poured onto saturated NH₄Cl/EtOAc. The aqueous layer was extracted 3 times (X) with EtOAc. The combined organics were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. Purification of the crude residue on silica gel (9:1 hexanes-EtOAc) provided 5.19g (77%) of title compound in the form of a white solid.

B.



To a suspension of isopropyltriphenylphosphonium iodide (6.48g, 15 mmol) in THF (45 ml) at -78°C was added n-BuLi (2.5 M in hexanes, 6.6 ml, 16.5 mmol). The resulting mixture was warmed to 0°C and stirred 30 minutes. To the reaction mixture was added a solution of tert-butyl-3,5-dichlorocinnamic ester (4.11 g, 15 mmol) in THF (30 ml). The reaction mixture was stirred 2 hours at 0°C, then slowly warmed to 25°C and stirred overnight. The reaction mixture was poured onto 10% H₂SO₄/EtOAc. The aqueous layer was extracted 3X with EtOAc. The combined organics were washed with saturated NaHCO₃, brine, and H₂O, dried over NaSO₄, and concentrated in vacuo. The crude residue was used without further purification: ¹H NMR (CDCl₃) δ 7.32 (1H, s) 7.30-7.27 (2H, m), 2.72 (1H, d, J = 8.9 Hz), 2.28 (1H, d, J = 8.9 Hz), 1.71 (9H, s), 1.51 (3H, s), 1.08 (3H, s).


C.



- The crude ester from Step B (ca. 25 mmol) was dissolved in 1:1 trifluoroacetic acid-CH₂Cl₂ (25ml) at 25°C. The resulting solution was stirred 1 hour at 25°C. The reaction mixture was concentrated in vacuo. The crude residue was partitioned between 10% NaOH and Et₂O. The aqueous layer was extracted 3X with ether. The pH of the aqueous layer was adjusted to 4 and was extracted 10X with EtOAc. The combined organics were dried over MgSO₄ and concentrated in vacuo to afford 2.32 g (71% over two steps) of a white solid: ¹H NMR (CDCl₃) δ 7.32 (1H, s) 7.30-7.27 (2H, m), 2.77 (1H, d, J = 8.9 Hz), 2.20 (1H, d, J = 8.9 Hz), 1.48 (3H, s), 1.05 (3H, s).

15


D.



- To a solution of acid from Step C (425 mg, 1.6 mmol) in DMF 5 ml at 25°C was added carbonyldiimidazole (313 mg, 1.9 mmol). The resulting solution was stirred 1 hour at 25°C. To the reaction mixture was added guanidine carbonate (609 mg, 3.2 mmol). The reaction mixture was stirred overnight at 25°C. The reaction mixture was poured onto H₂O/EtOAc. The aqueous layer was extracted 3X with EtOAc. The combined organics were washed 2X with brine, dried over Na₂SO₄, and concentrated in vacuo to provide 373 mg (77%) of title compound in the form of a yellow oil. The crude product was separated into its two enantiomers (Chiralpak AD 5 x 50 cm, 9:1 hexanes-EtOH, 0.2% NEt₃, isocratic program): ¹H NMR (CDCl₃) δ 9.02 (1H, bs), 7.71 (2H, bs), 7.37 (1H, s) 7.30-7.25 (2H, m), 2.72 (1H, d, J =


8.9 Hz), 2.18 (1H, d, $J = 8.9$ Hz), 1.48 (3H, s), 1.05 (3H, s); LCMS ($M+1$) = 301.

Example 147




5

A.



To a solution of 2,3-dihydrobenzofuran-4-aldehyde (1g, 6.7 mmol) (Example 2, Part C) and dimethyl malonate 0.89 g, 6.7 mmol) in benzene (30 mL) was added piperidine (0.11 g, 1.4 mmol) and acetic acid (0.40 g, 6.7 mmol). The resulting solution was stirred for 18 hr with continuous removal of water. The solution was cooled to ambient temperature and concentrated. The residues was chromatographed on silica gel (ethyl acetat:hexane, 3:7) to give the title compound (1.5g).

B.




20

To a solution of Part A compound (1.3 g, 5.0 mmol) and 2-nitropropane (0.88g, 9.9 mmol) in DMSO (20 mL) was added potassium t-butoxide (1.11 g, 9.9 mmol). The resulting mixture was stirred at ambient temperature for 65 hr and diluted with ethyl acetate. The solution was washed with 1N HCl. The organic layer was dried and concentrated. The residue was chromatographed on silica gel (ethyl acetate:hexane, 15:85) to give the title compound (0.82 g).


30

C.




To a solution of Part B compound (0.1 g, 0.3 mmol) in DMSO (10 mL) was added sodium cyanide (32 mg, 0.65 mmol). The mixture was stirred for 4 hr at 15°C and cooled to ambient temperature and diluted with ethyl acetate. The mixture was extracted with water. The aqueous layer was acidified with 1N HCl and extracted with ethyl acetate. The organic layer was dried and concentrated to give the title compound (45 mg) as 8 to 1 of trans to cis isomers.

D.




To a solution of Part C compound (45 mg, 0.2 mmol) in DMF (5 mL) was added carbonyl-diimidazole (38 mg, 0.2 mmol). The resulting solution was stirred for 1 hr at ambient temperature and guanidine (14 mg, 0.2 mmol) was added. The resulting solution was stirred for 16 hr at ambient temperature and diluted with ethyl acetate. The solution was washed with water. The organic layer was dried and concentrated. The residue was purified by reverse phase preparative HPLC to give the title compound (M+H)⁺=274.

25

Example 148


A.



3a-9a-cis-3a,4,9,9a-Tetrahydro-2,2-dimethyl-2H-naphtho[2,3-d]-1,3-dioxol-5-ol (described in J. Med. Chem., 1978, 21, 913) (200 g, 0.908 mole), methanol (500 mL), and distilled water (170 mL) were charged in a 1000 mL three-neck round bottom flask equipped with a mechanical stirrer, a reflux condenser, and a digital thermometer probe at room temperature to obtain a suspension. Trifluoroacetic acid (15 mL) was added to the suspension with stirring. The suspension was heated to reflux at 62.5°C for 3 hr. The reaction mixture was cooled to ambient temperature. A white suspension appeared. Methanol and trifluoroacetic acid were removed under reduced pressure. Water (360 mL) was added to the suspension with stirring. The suspension was then heated to 90°C to dissolve the precipitate. The mixture was stirred for 30 min at 90°C and allowed to cool to ambient temperature over 30 min and set aside at ambient temperature for 16 hr. The resulting crystals were filtered and washed with cold distilled water (100 mL). The crystals were dried in vacuo at room temperature overnight to give 155.9 g of the desired triol (95.3% yield) as gray needles.

25

B.




Part A triol (140 g, 777 mmol), tetrahydrofuran (330 mL) and distilled water (660 mL) were charged to a 2000 mL three-neck round bottom flask equipped with a mechanical stirrer and a digital thermometer at ambient temperature. A suspension was formed. The suspension was cooled to 0°C by using an ice-water bath. Sodium periodate (179.47 g,

839 mmol) was added portionwise (~10 g each) over a period of 80 minutes. The reaction mixture was stirred for additional 40 minutes at 0°C. The precipitate was filtered and washed with ethanol (2 x 125 mL). The filtrate and the
5 ethanol solutions were combined and saved.

Absolute ethanol (700 mL) in a 3000 mL three-neck round bottom flask equipped with a mechanical stirrer, a digital thermometer, and a pressure equalizing addition funnel was cooled to -6°C by using a dry-ice acetone bath.
10 Sodium borohydride (88.18 g, 2.331 mol) was added and the resulting suspension was stirred for 5 min at -6°C. To this was added the dialdehyde solution (1200 mL) in ethanol (from above) dropwise over a period of 80 minutes with the temperature maintained between -3 and 0°C. The mixture was
15 stirred for additional 40 minutes at 0°C. Acetone (300 mL) was added dropwise to above solution over a period of 40 minutes and while keeping the temperature below 3°C. The reaction mixture was stirred for additional 0.5 hrs below 3°C. It was then warmed to room temperature and
20 stirred for 30 minutes.

Saturated ammonium chloride solution (500 mL) was then added at room temperature and the white precipitate was filtered and wash with ethanol (2 x 100 mL). The filtrate and the ethanol solutions were combined and the organic
25 solvent removed under reduced pressure. Solid ammonium chloride (50 g) was added to the residue and the residue extract with ethyl acetate (5 x 400 mL). The combined organic layers were washed with 2:1 mixture of
30 mixture of water:saturated sodium hydrogensulfite (300 mL), 1:1 mixture of water:brine (300 mL), and brine (2 x 300 mL). The organic phase was dried over magnesium sulfate and filtered. The solvent was removed under reduced pressure to give 136.13 g of the desired compound in 94.8% yield.

C.




Part B triol (134 g, 735 mmol), pyridine (250 mL), and dichloromethane (350 mL) were charged in a 2000 mL three-neck round bottom flask equipped with a mechanical stirrer, a digital thermometer, and a pressure equalizing addition funnel at room temperature. The mixture was cooled to -40°C by a dry-ice acetone bath. To this was added a solution of tosyl chloride (274.78 g, 1.442 mol) in pyridine (70 mL) and dichloromethane (400 mL) over a period of 170 minutes at -40°C with good stirring. The mixture was stirred for an additional 3.5 hr at -35°C. Additional tosyl chloride (16.81 g, 88.2 mmol) was then added to the reaction mixture at -40°C and the reaction mixture stirred for 30 minutes. The reaction mixture was warmed to -10°C and dichloromethane (1500 mL) was added at -10°C. The reaction mixture was warmed to room temperature, washed with 2N HCl (4 x 650 mL), saturated NaHCO₃ (650 mL), brine (650 mL), dry over Na₂SO₄, and filtered. Solvent was removed under reduced pressure to give 360 g of crude ditosylate as a light yellowish residue which was used for the next step without any purification.

The crude ditosylate and methanol (2000 mL) were charged in a 3000 mL three-neck round bottom flask equipped with a mechanical stirrer, a digital thermometer, and a pressure equalizing addition funnel. The mixture was cooled to 0°C by an ice-water bath. Anhydrous potassium carbonate (111.74 g, 809 mmol) was added portionwise to the methanol solution at 0°C and the reaction mixture stirred at 0°C for 2 hr. The reaction mixture was warmed to room temperature and stirred for additional 2 hr. The white precipitate was filtered and washed with ethyl acetate (2 x 100 mL). The filtrates were combined and concentrated to ~500 mL. The resulting precipitate was filtered and washed with 1:1 methanol:water (100 mL). The residue was dried in


vacuum (~1 mmHg) for 3.5 hrs and over house vacuum overnight to give the desired compound (197.0 g, 84% yield).

5 D.




The Part C tosylate (100 g, 314 mmol) was dissolved in THF (1200 mL) in a 2000 mL three-neck round bottomed flask equipped with a mechanical stirrer, a digital thermometer, and a pressure equalizing addition funnel at room temperature. The reaction mixture was cooled to 0°C by an ice-water bath. To this was added a solution of *t*-BuOK (1 M, 345.5 mL) in THF dropwise at 0°C over a period of 110 min. The reaction mixture was warmed to ambient temperature and stirred for additional 2 hr. Water (350 mL) and EtOAc (600 mL) were added and the two layers were separated. The aqueous layer was further extracted with EtOAc (2 x 150 mL). The combined EtOAc layers were washed with brine (2 x 150 mL) dried over MgSO₄ and filtered. The solvent was removed under reduced pressure to give 46 g of the title styrene in 100% yield.

E.




25 To a flame-dried 1L three necked round bottom flask equipped with a magnetic stirrer was added *N,N*,2-trimethyl propionamide (17.8mL, 0.138mol) and anhydrous methylene chloride (200mL). The mixture was stirred to give a solution under argon and cooled to -15°C. Trifluoro-
30 methanesulfonic anhydride (26mL, 0.154mol) was added via syringe and the resulting mixture was stirred at -15°C for



10 minutes. A solution of (from Part D) (17.5g, 0.12mol), and collidine (21mL, 0.155mol) in anhydrous methylene chloride (30mL) was added at -15°C. After the addition was completed, the reaction mixture was heated to reflux and stirred for 20 hours. The solvent was removed on a rotary evaporator and the residue oil was washed with ether (3x100mL). The residue was then dissolved in methylene chloride (150mL). Water (150mL) was added and the mixture was refluxed for 6 hours. After cooling to room temperature, the phases were separated. The aqueous layer was extracted with methylene chloride (2x100mL). The rich organic layers were combined, washed with brine (200mL) and dried over anhydrous sodium sulfate. After removal of sodium sulfate by filtration, the filtrate was concentrated to give an oil which was purified by silica gel chromatography using 5-10% EtOAc/hexane as the eluent to give 19.0g (73%) title compound as a white crystalline compound. HPLC, 100A% at 220nm. ¹H NMR (CDCl₃) δ, 7.14 (t, J=7.8Hz, 1H), 6.72 (t, J=8.2Hz, 2H), 4.52-4.65 (m, 2H), 3.50 (dd, J=7.0, 16.4Hz, 1H), 3.08-3.41 (m, 4H), 1.38 (s, 3H), 0.83 (s, 3H).


F.



To an oven dried 3L three necked round bottom flask equipped with a mechanical stirrer was placed Part E compound (20.0g, 92.47mmol) and anhydrous THF (925mL). The mixture was stirred to give solution and cooled to -65°C. A solution of 1N LiHMDS in THF (101.7mL, 101.7mmol) was added over 15 minutes while keeping the pot temperature below -55°C. The resulting mixture was stirred at -70°C for 30 minutes and 0°C for 15 minutes. After cooling back

to -70°C , a solution of N-bromosuccinimide (NBS) (16.4g, 92.2mmol) in anhydrous THF (230mL) was added over 5 minutes. After addition was completed the cooling bath was replaced with an ice-water bath and the reaction mixture was stirred to 0°C for 10-20 minutes at which time HPLC indicated that the bromination was complete. A solution of sodium hydroxide (23.1g, 577.5mmol) in DI water (230mL) was added at 0°C and the resulting reaction mixture was stirred at room temperature for 15-30 minutes at which time the ring contraction reaction was complete. THF was removed on a rotary evaporator and the rich aqueous was washed with MTBE (2x125mL). The residual organic solvent was removed on rotary evaporator and the rich aqueous was diluted with DI water (250mL). The pH of the resulting rich aqueous was then adjusted from ~ 12.5 to 1.0 using conc. HCl (47mL). The resulting slurry was cooled to 0°C and stirred for 30 minutes. The slurry was filtered, washed with ice-cold DI water (3x50mL) and suction dried for 18 hours to give 20.6g (96%) of title compound as white crystalline compound. HPLC 97.7A% at 220nm. ^1H NMR (CDCl_3) δ 7.07 (t, $J=7.8\text{Hz}$, 1H), 6.71 (d, $J=7.9\text{Hz}$, 1H), 6.59 (d, $J=7.6\text{Hz}$, 1H), 4.61 (t, $J=8.9\text{Hz}$, 2H), 2.23-3.32 (m, 1H), 3.07-3.15 (m, 1H), 2.61 (d, $J=5.9\text{Hz}$, 1H), 2.00 (d, $J=5.9\text{Hz}$, 1H), 1.47 (s, 3H), 1.00 (s, 3H). ^{13}C NMR (CDCl_3) δ 179.3, 160.2, 134.4, 128.4, 127.5, 120.1, 108.3, 71.5, 37.1, 31.6, 30.8, 29.3, 22.4, 20.9.

G. Resolution of Part F Acid



To a stirring solution of Part F acid (14.0 g, 60.27 mmols) in absolute ethanol (420 mL) at 55°C was added D-(+)- α -methylbenzylamine (9.2 mL, 72.33 mmols) in one portion. To the solution was added a seed crystal then the


mixture was allowed to slowly cool to room temperature with stirring over 2 hrs, then the mixture was stirred an additional 18 hrs at room temperature. The solid was isolated by filtration, washed with hexanes (3 x 5 pad
5 volumes), air-dried (30 min), dried under vacuum (<2 mm Hg, 16 hr) to afford 7.89 g of amine salt as a white powder (37% yield; 50% theoretical maximum).

To a suspension of amine salt (3.70 g, 10.47 mmol) in EtOAc (50 mL) was added 1N HCl (25 mL) at room
10 temperature. After mixing vigorously, the aqueous solution was removed. The organic solution was washed with sat. aq. NaCl (25 mL), dried (anhyd. MgSO₄), filtered, and concentrated *in vacuo* to afford 2.42 g of chiral acid as a white solid (99% yield).

15 ¹H NMR (270 MHz, CDCl₃): δ 7.05 (dd, J=7.9 and 7.7 Hz, 1H), 6.68 (d, J=7.9 Hz, 1H), 6.58 (d, J=7.7 Hz, 1H), 4.59 (dd, J=9 and 9 Hz, 2H), 2.9-3.4 (m, 2H), 2.59 (d, J=5.9 Hz, 1H), 1.98 (d, J=5.9 Hz, 1H), 1.45 (s, 3H), and 0.98 (s, 3H).

20

H.



To a stirring solution of Part G chiral carboxylic acid (12g, 51.7mmol) in anhydrous DMF (70 mL) was added CDI
25 (10.05g, 62.04 mmol) in small portions. After 2 h. under argon at RT, a solution of free base guanidine (6.1 g, 103.4 mmol) in DMF (20 mL) was added. Stirring was continued for 18h at RT. The reaction mixture was diluted with ethyl acetate and washed with water (x 5); followed by
30 brine (x 1); dried over MgSO₄; filtered and solvent was removed *in vacuo*, affording the crude product as a white foam. The crude product was subjected to reversed phase preparative HPLC (C18 column/water-MeOH-TFA 80:20:0.1 to 10:90:0.1 gradient) to afford a TFA salt of the title
35 compound. This was dissolved in EtOAc, adjusted to pH 7-8

with saturated Na_2CO_3 aqueous solution, diluted with water, the organic layer was dried over MgSO_4 ; filtered and concentrated in vacuo, affording the title compound as a free base. This was taken in THF and treated with 14 mL 4N HCl in dioxane at 0°C with swirling. The solvent was removed in vacuo and the residue was lyophilized from water to afford the title compound as the HCl salt (white solid, 8.6 g, 54 % yield).

MS m/e $(M+H)^+$ 274⁺; ^1H NMR (270MHz; CDCl_3) δ 11.8 (s, 1H); 8.4 (bs, 4H); 7.26 (s, CHCl_3); 7.01 (t, $J=7.84$, 1H); 6.67 (d, $J=7.94$, 1H); 6.55 (d, $J=7.65$, 1H); 4.58 (t, $J=9.2$, 2H); 3.25 (m, 1H); 5.05 (m, 1H); 2.71 (d, $J=5.6$, 1H); 2.12 (d, $J=5.7$, 1H); 1.4 (s, 3H); 0.99 (s, 3H).

^{13}C NMR (270MHz; CDCl_3) 20.52, 22.21, 29.29, 33.22, 34.47, 37.46, 71.43, 77.1, 77.42, 77.75, 108.6, 119.9, 127.4, 128.5, 133.5, 156.4, 160.3, 173.9. Optical rotation $[\alpha]_D + 7.3^\circ$ $c = 1$ CHCl_3 .










20

Elemental Analysis: $\text{C}_{15}\text{H}_{19}\text{N}_3\text{O} \cdot 1.0 \text{ HCl} \cdot 0.806 \text{ H}_2\text{O}$










	%C	%H	%N
Calculated:	55.55	6.72	12.96
Found:	55.55	6.43	13.03










25









The following compounds were prepared using procedures described above.






Example No.	Structure	Characterization (MS)
149		(M+H) ⁺ 298
150		(M+H) ⁺ 298
151		(M+H) ⁺ 266
152		(M+H) ⁺ 276
153		(M+H) ⁺ 267
154		(M+H) ⁺ 266
155		(M+H) ⁺ 329
156		(M+H) ⁺ 267
157		(M+H) ⁺ 267


158		(M+H) ⁺ 329
159		(M+H) ⁺ 311
160		(M+H) ⁺ 301
161		(M+H) ⁺ 249
162		(M+H) ⁺ 267
163		(M+H) ⁺ 333
164		(M+H) ⁺ 367
165		(M+H) ⁺ 284
166		(M+H) ⁺ 317
167		(M+H) ⁺ 283

168		(M+H) ⁺ 297
169		(M+H) ⁺ 332
170		(M+H) ⁺ 285
171		(M+H) ⁺ 274
172	 Chiral	(M+H) ⁺ 274
173		(M+H) ⁺ 274 ⁺
174		(M+H) ⁺ 303
175		(M+H) ⁺ 232
176		(M+H) ⁺ 233

177		(M+H) ⁺ 233
178		(M+H) ⁺ 233
179		(M+H) ⁺ 302
180		(M+H) ⁺ 302
181		(M+H) ⁺ 298
182		(M+H) ⁺ 281
183		(M+H) ⁺ 297
184		(M+H) ⁺ 318
185		(M+H) ⁺ 264


186		(M+H) ⁺ 278
187		(M+H) ⁺ 292
188		(M+H) ⁺ 278
189		(M+H) ⁺ 266
190		(M+H) ⁺ 295
191		(M+H) ⁺ 272
192		(M+H) ⁺ 272
193		(M+H) ⁺ 300

194		(M+H) ⁺ 300
195		(M+H) ⁺ 263
196		(M+H) ⁺ 296
197		(M+H) ⁺ 296
198		(M+H) ⁺ 292

Example 199

5


A.



To a solution of 2-chloroethyl-4-fluorophenylketone (2g, 10.7 mmol) in 1:1 solution of THF:ethanol (20 mL) at 0°C was added sodium borohydride (0.49g, 12.8 mmol). The resulting solution was stirred for 3 h at 0°C and was quenched with saturated ammonium chloride (40 mL). The mixture was stirred for 30 min at ambient temperature. The

organic layer was separated and aqueous layer was extracted with diethyl ether. The combined organic layers were dried and concentrated to give the corresponding alcohol, which did not further characterized. To the alcohol concentrated
5 HBr (10 mL) was added. The mixture was stirred for 3 h at ambient temperature and poured into ice (ca 30g) with potassium carbonate (10g). The mixture was extracted with ethyl acetate. The organic layers were dried and concentrated. The residue was chromatographed on silica
10 gel (ethyl acetate:hexane, 1:9) to give 1.2 g (44%) of title compound.


B.



15 To a solution of Part A compound (1.16g, 4.6 mmol) in dioxane (20 mL) was added diethyl malonate (0.78g, 4.9 mmol) and sodium hydride (0.28g, 11.6 mmol). The mixture was stirred for 13 h at reflux and cooled to ambient temperature. The mixture was diluted with ethyl acetate
20 and washed with brine. The organic layer was dried and concentrated. The residue was chromatographed on silica gel (ethyl acetate:hexane, 5:95) to give 0.72 g (53%) of title compound.

25


C.



A mixture of Part B compound (0.5g, 1.7 mmol) and lithium chloride (0.15g, 3.4 mmol) in 10% aqueous DMSO (10mL) was stirred for 7 h at reflux and cooled to ambient
30 temperature. The solution was diluted with ethyl acetate and washed with brine. The organic layer was dried and concentrated. The residue was chromatographed on silica

gel (ethyl acetate:hexane, 5:95) to give 0.23 g (61%) of title compound.

D.




5


To a solution of Part C compound (0.23g, 1 mmol) in DMF (5 mL) was added guanidine (0.3 g, 5.1 mmol). The mixture was stirred for 18 h at ambient temperature and diluted with ethyl acetate. The mixture was washed with water and dried and concentrated. The residue was purified using reverse phase preparative HPLC to give 0.1 g of the desired product. ((M+H)⁺=236).

15

Example 200



A.




20

Methyl 3-Amino-2,5-dichlorobenzoate

HCl gas was bubbled through a solution of 2,5-dichloro-3-nitrobenzoic acid (20 g) in 200 mL MeOH and the reaction mixture was 100°C (bath temperature) to remove approximately 80 mL solvent. The mixture was allowed to come to RT, added 80 mL MeOH and bubbled additional HCl through the reaction mixture. The mixture was heated again to 100°C to remove the volatiles. The residue was dissolved in 250 mL MeOH, followed by the addition of 10 g RaNi. The mixture was stirred at RT under hydrogen for 16

h, filtered to remove the catalyst and the filtrate was concentrated in vacuo to afford the title compound as an off-white solid (18.5 g).

5 B.




2,5-Dichloro-3-(carboxymethyl)benzenesulfonic acid

A solution of sodium nitrite (1.68 g, 24 mmol) in 5 mL water was added dropwise to a stirred mixture of the Part A compound (4.4 g, 20 mmol), conc. sulfuric acid (15 mL), 89% phosphoric acid (20 mL) and water 10 mL at 0-5°C over 15 minutes. Stirring was continued at 0-5°C for 5 h and the reaction mixture was kept at -16°C for 14 h. To this was added 20 mL precondensed SO₂ at -15°C in one portion and the resulting mixture was immediately poured in to a flask containing Cu powder (200 mg) and CuSO₄ heptahydrate (11.12 g, 40 mmol) with stirring. The resulting foamy mixture was stirred at RT for 4 h, diluted with water and extracted with ethyl acetate. The ethyl acetate layer was extracted with 2 N NaOH, the NaOH layer was acidified with 20% sulfuric acid and extracted with ethyl acetate. The ethyl acetate layer was dried over magnesium sulfate and concentrated to give the title compound as a yellow solid (2.9 g).

25

C.




Methyl 2,5-Dichloro-3-(carboxymethyl)-benzenesulfonate

30 To a solution of Part B compound (1 g) in 5 mL DMF was added potassium carbonate (770 mg) and MeI (795 mg) and

the resulting mixture was stirred at RT for 24 h. The mixture was diluted with water, extracted with ethyl acetate, the organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo to afford the title compound as a yellow gummy oil (1 g).


D.




Methyl 2,5-Dichloro-3-formylbenzenesulfonate

To a solution of the Part C ester (1g, 3.53 mmol) in 25 mL toluene was added a solution of diisobutylaluminum hydride (DIBAL) in toluene (1.5 M, 5.2 mL, 7.8 mmol) at -78°C and the mixture was stirred at that temperature for 15 minutes. The mixture was allowed to come to -25°C, stirred for 15 min., cooled to -78°C and quenched by adding 5 mL MeOH. The reaction mixture was diluted with EtOAc, washed sequentially with dilute HCl, saturated NaHCO₃ and brine. The organic layer was dried over magnesium sulfate and concentrated. This compound was oxidized as reported in Example 2, Step C to give the title compound as a thick pale oil (0.9g).


E.



The title compound was prepared employing the Part D intermediate and the procedures set out hereinbefore.

Example 201

A.




5

2,5-Dichloro-4-fluorobenzyl alcohol

A solution of 2,5-dichloro-4-fluorobenzoic acid (4.1 g, 19.6 mmol; prepared as described in the literature: Feit, P. W. et al, J. Med. Chem. 1972, Vol. 15, 79-83) in 100 mL THF was treated with 24.5 mL borane methylsulfide complex in THF (2M, 24.5 mL, 49 mmol) at 0-5°C. The mixture was allowed to come to RT, stirred for 14 h at RT and quenched by adding saturated NaHCO₃ and 10 mL MeOH. The mixture was extracted with ethyl acetate, the organic layer was washed sequentially with 10% HCl and saturated NaHCO₃ solutions, dried over magnesium sulfate and concentrated to give 3.65 g of the title compound as a white solid.

20

B.

2,5-Dichloro-4-fluorobenzaldehyde


To a solution of oxalyl chloride (1.72 mL, 19.74 mmol) in 20 mL methylene chloride at -78°C was added a solution DMSO (2.8 mL, 39.5 mmol) in 3 mL methylene chloride. The mixture was stirred for 5 minutes at -78°C followed by the addition of a solution of Part A 2,5-dichloro-4-fluorobenzyl alcohol (3.5 g, 17.95 mmol) from above in 15 mL methylene chloride. The mixture was stirred at -40°C for 15 min., cooled to -78°C followed by the addition of triethylamine (8.26 mL, 59.2 mmol). The mixture was allowed to come to RT, washed sequentially with 10% HCl,

30

saturated sodium bicarbonate solution and water. The organic layer was dried over magnesium sulfate and concentrated to afford the title compound 3.39 g as a white solid.

5


C.



The title compound was prepared employing the Part B intermediate and the procedures set out hereinbefore.


10

Example 202



15

A.




trans -Ethyl-(2-chloro)-α-methylcinnamate


A solution of 2-chlorobenzaldehyde (1.29 g, 9.2 mmol) and (carbethoxyethylidene)-triphenylphosphorane (5.0 g, 13.8 mmol) in dichloromethane (40mL) was heated while stirring at 40°C for 18 hours. After the reaction solution cooled down to RT, the solution was concentrated in vacuo to remove solvent. The resulting off-white solid was subjected to flash chromatography (silica gel, 7:3 hexane: ethyl acetate) to afford the title compound (1.88 g, 8.34 mmol, 91% yield) as a clear heavy oil.

25


B.




The title compound was prepared employing the Part A
 5 intermediate and the procedures set out hereinbefore
 ((M+H)⁺=252).

Example 203

10

Example 204

A.




15

2-(3-Bromo-5-chlorophenyl)-1,3-dioxalane

To a solution of 3-bromo-5-chlorobenzaldehyde
 (prepared using the methodology described in patent WO
 9708145, 970306, by Ruminski, Peter et al; 1.91 g, 8.7
 20 mmol) in toluene (150mL) was added ethylene glycol (2.91
 mL, 52 mmol) and p-toluene sulfonic acid monohydrate (50mg,
 0.26mmol). The reaction flask was attached to a Dean-Stark
 trap to remove water. After refluxing for 18 hours, the
 reaction mixture was washed with saturated NaHCO₃ solution
 25 (2x). The organic layer was dried over MgSO₄, filtered,
 and concentrated *in vacuo* to remove solvent and the
 resulting oil was subjected to flash chromatography (silica

gel, 9:1 hexane:ethyl acetate) to afford the title compound (1.95g, 7.4 mmol, 85% yield) as a light yellow oil.

B.




5

2-(3-Chloro-[5-(1H-pyrazol-1-yl)]phenyl)-1,3-dioxalane

A solution of pyrazole (258 mg, 3.79mmol) in DMF (5mL) was added dropwise at RT to a solution of NaH (100mg, 4.17mmol) in DMF (10mL) while stirring. After stirring for an additional 5 min, a solution of Part A 2-(3-bromo-5-chlorophenyl)-1,3-dioxalane (1g, 3.79 mmol) in DMF (10mL) and CuI (145mg, 0.76 mmol) were added to the reaction solution. The reaction mixture was heated to 150°C for 7 h. Cooled to RT, the reaction mixture was diluted with dichloromethane and washed with water. The layers were separated and the water layer was backwashed with fresh dichloromethane (2x). All the organic layers were combined, dried over anhydrous MgSO₄, filtered and the solvent was removed in vacuo affording an oil. Flash chromatography (silica gel, 8:2 hexane:ethyl acetate) was used to isolate the title compound as an off-white solid (618mg, 2.47 mmol, 65% yield).

25

C.




3-Chloro-5-(1H-pyrazol-1-yl)benzaldehyde

Part B 2-(3-chloro-[5-(1H-pyrazol-1-yl)]phenyl)-1,2-dioxalane (669mg, 2.67 mmol) was stirred at room temperature for 2h. in 1N HCl (30mL) and dioxane (4mL). The reaction mixture was neutralized with saturated NaHCO₃


solution and extracted with ethyl acetate (3x). All the organic layers were combined and dried over anhydrous MgSO_4 , filtered and the solvent was removed *in vacuo* affording the title compound as an off-white solid (552 mg, 2.67 mmol, 100% yield):

D.




10

E.




The title D and E compounds were prepared employing the Part C intermediate and the procedures set out hereinbefore.

Example 205

20


A.

Ethyl 2,3-cis-diphenylcyclopropane carboxylate


A solution of tris(4-bromophenyl)aminium hexachloroantimonate (245 mg) in dichloromethane (10 mL)

was cooled in an ice bath and purged with nitrogen for 1h. To this was added a solution of *cis*-stilbene (180 mg) and ethyl diazoacetate (1.14 g) in dichloromethane (10mL). Reaction mixture was stirred overnight and allowed to warm
 5 to ambient temperature. Reaction was quenched with saturated potassium carbonate solution in methanol (5mL), diluted with water and extracted with ethyl acetate. Organic layer was separated, dried over magnesium sulfate and concentrated to give crude title compound (0.1 g) which
 10 was used without purification.

B.




15 The title compound was prepared employing the Part A intermediate and the procedures set out hereinbefore.

Example 206

20

A.


2,3-Dihydrobenzofuran-7-carboxaldehyde

A solution of 2,3-dihydrobenzofuran-7-carboxylic
 25 acid (1.0g, 6.09 mmol, 1.0 equiv.), dimethylmethoxyamine hydrochloride (654 mg, 6.7 mmol, 1.1 equiv.), diisopropylethylamine (DIEA) (2.35 ml, 13.4 mmol, 2.2 equiv.), benzotriazole-1-yl-oxy-tris-pyrrolidino-

phosphonium hexafluorophosphate (PyBOP) (3.48g, 6.7 mmol, 1.1equiv.) and 4-dimethylaminopyridine (DMAP) (74 mg, 0.67 mmol, .1 equiv.) in anhydrous THF (20 ml) was stirred for 18hr under argon. The reaction mixture was then diluted with EtOAc (100 ml) and washed with aqueous sat. NaHCO₃ (2x150 ml) and aqueous 1N HCl (2 x 150 ml), the organic layer was dried over MgSO₄, filtered and solvent removed. yield : 1.06 mg, 84 %. LS-MS calcd 207, found 208.

To a solution of the amide (950 mg, 4.59 mmol, 1.0 equiv.) in anhydrous THF (20 ml) was cooled to -5C under argon, was slowly added 1.0 M LAH in THF (9.1 ml, 9.14 mmol, 1.5 equiv.), the reaction mixture was stirred for 1 hr at -5C. A solution of aqueous 1 N HCl (150 ml) was slowly added to the reaction mixture, and extracted with EtOAc (50 ml). The organic layer was washed with aqueous 1 N HCl (150 ml), the organic layer was collected and dried over MgSO₄, filter and solvent removed under reduced pressure to yield the aldehyde. Yield: 620 mg, 91%. LR-MS calcd 148, found 149.










B.



















The Part A intermediate was used in preparing the title compound employing the procedures set out hereinbefore.









Examples 207 to 257











The following compounds were prepared from the corresponding aldehydes, acids or esters using the procedures described above.









Example No.	Structure	Characterization (MS)
207		(M+H) ⁺ 260
208		(M+H) ⁺ 232
209	 chiral	(M+H) ⁺ 232
210	 chiral	(M+H) ⁺ 232
211		(M+H) ⁺ 272
212		(M+H) ⁺ 306
213		(M+H) ⁺ 272
214		(M+H) ⁺ 252
215		(M+H) ⁺ 252

216		(M+H) ⁺ 272
217	 chiral enantiomer A	(M+H) ⁺ 272
218	 chiral enantiomer B	(M+H) ⁺ 272
219		(M+H) ⁺ 218
220		(M+H) ⁺ 272
221		(M+H) ⁺ 218
222		(M+H) ⁺ 301
223		(M+H) ⁺ 240
224		(M+H) ⁺ 240
225		(M+H) ⁺ 260

226		(M+H) ⁺ 328
227		(M+H) ⁺ 340
228		(M+H) ⁺ 375
229		(M+H) ⁺ 375
230		(M+H) ⁺ 375
231		(M+H) ⁺ 294


232		(M+H) ⁺ 272
233		(M+H) ⁺ 264
234		(M+H) ⁺ 238
235		(M+H) ⁺ 260
236		(M+H) ⁺ 252
237		(M+H) ⁺ 314
238		(M+H) ⁺ 286
239		(M+H) ⁺ 286

240		(M+H) ⁺ 252
241		(M+H) ⁺ 304
242		(M+H) ⁺ 232
243		(M+H) ⁺ 350
244		(M+H) ⁺ 290
245		(M+H) ⁺ 252
246		(M+H) ⁺ 318
247		(M+H) ⁺ 304
248		(M+H) ⁺ 344
249		(M+H) ⁺ 332

250		(M+H) ⁺ 332
251		(M+H) ⁺ 394
252		(M+H) ⁺ 394
253		(M+H) ⁺ 394
254		(M+H) ⁺ 248
255		(M+H) ⁺ 246
256		(M+H) ⁺ 246
257		(M+H) ⁺ 266


Example 258

(S)-N-(Aminoiminomethyl)-1-(3-chloro-4-nitrophenyl)-2-pyrrolidinecarboxamide




5

A. (S)-1-(3-Chloro-4-nitrophenyl)-2-pyrrolidinecarboxylic acid 1,1-dimethylethyl ester



10


To a solution of L-proline tert-butyl ester



(1.06 g, 7.5 mmol) in dry DMSO (10 ml) were added 3-chloro-4-nitrofluorobenzene (1.48 g, 8.4 mmol) and diisopropylethylamine (2.60 mL, 15 mmol). The resulting solution was heated at 110°C in a sealed tube for 48 hours. The reaction mixture was cooled to room temperature and partitioned between brine and ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined organic extracts were washed with water, dried over sodium sulfate, and concentrated in vacuo. Purification of the crude residue on silica gel (7:3/EtOAc-hexanes) provided 1.98 g (90%) of a pale yellow solid.

¹H NMR (CD₃OD): δ 8.13 (1H, d, J=2.7 Hz), 8.02 (1H, dd, J=9.3 Hz, 2.7 Hz), 6.92 (1H, d, J=9.3 Hz), 5.01 (1H, dd, J=9.2 Hz, 3.9 Hz), 3.35 (1H, m), 3.30 (1H, m), 2.31 (1H, m), 2.07 (1H, m), 2.02 (2H, m), 1.38 (9H, s).

B. (S)-1-(3-Chloro-4-nitrophenyl)-2-pyrrolidinecarboxylic acid




5

The Part A compound (0.44 g, 1.5 mmol) was dissolved in 1:1 CH₂Cl₂-trifluoroacetic acid (5 mL). The resulting solution was stirred at room temperature for 12 hours. The reaction mixture was concentrated in vacuo and azeotroped with toluene to afford 350 mg of the title compound as a brown solid.

¹H NMR (CD₃OD): δ 8.26 (1H, d, J=2.7 Hz), 8.17 (1H, dd, J=9.3 Hz, 2.7 Hz), 7.19 (1H, d, J=9.3 Hz), 5.20 (1H, dd, J=9.2 Hz, 3.9 Hz), 3.94 (1H, m), 3.77 (1H, m), 2.64 (1H, m), 2.27 (1H, m), 2.19 (3H, m).

C. (S)-N-(Aminoiminomethyl)-1-(3-chloro-4-nitrophenyl)-2-pyrrolidinecarboxamide



To a solution of Part B compound (0.36 mg, 1.5 mmol) in dry DMF (5 mL) at room temperature was added 1,1'-carbonyldiimidazole (0.29 g, 1.8 mmol). The resulting solution was stirred at room temperature for 2 hours, then cooled to 0°C. To the reaction mixture was added solid guanidine (0.44 g, 7.5 mmol). The resulting solution was warmed to room temperature and stirred for 12 hours. The

reaction mixture was partitioned between water and ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined organics were washed with brine, dried over sodium sulfate, and concentrated in vacuo.





- 5 Purification of the crude residue by preparative HPLC (C18 column/10:90:0.1 to 90:10:1 MeOH-water-TFA gradient) provided the desired product (110 mg, 27%) as white solid.










¹H NMR (CD₃OD): d 8.28 (1H, d, J=2.7 Hz), 8.19 (1H, dd, J=9.3 Hz, 2.7 Hz), 7.22 (1H, d, J=9.3 Hz), 5.31 (1H, dd, J=9.2 Hz, 3.9 Hz), 3.97 (1H, m), 3.79 (1H, m), 2.65 (1H, m), 2.30 (1H, m), 2.21 (2H, m). LRMS (M+H)⁺=312.










Examples 259 to 282



The following compounds (Examples 259 to 282) were prepared employing a procedure similar to that as set out in Example 258.


5

Example No.	Structure	Characterization (MS)
259		(M+H) ⁺ 343
260		(M+H) ⁺ 339
261		(M+H) ⁺ 382
262		(M+H) ⁺ 382


263		(M+H) ⁺ 420
264		(M+H) ⁺ 454
265		(M+H) ⁺ 454
266		(M+H) ⁺ 488
267		(M+H) ⁺ 343
268		(M+H) ⁺ 311
269		(M+H) ⁺ 311
270		(M+H) ⁺ 328
271		(M+H) ⁺ 488

272		(M+H) ⁺ 386
273		(M+H) ⁺ 278
274		(M+H) ⁺ 326
275		(M+H) ⁺ 311
276		(M+H) ⁺ 392
277		(M+H) ⁺ 454
278		(M+H) ⁺ 312
279		(M+H) ⁺ 346
280		(M+H) ⁺ 339

281		(M+H) ⁺ 343
282		(M+H) ⁺ 346

Example 283

A.




5

A mixture of ethyl 4-bromocinnamate (0.5 g, 2 mmol), sarcosine (0.19 g, 2.2 mmol), and paraformaldehyde (0.19 g, 6.4 mmol) in benzene (50 mL) was stirred for 10 hr at reflux with continuous removal of water. The mixture was cooled to ambient temperature and concentrated. The residue was chromatographed on silica gel (ethyl acetate) to give the desired product (0.21 g).

10

B.



15







To a solution of Part A compound (0.15g, 0.5 mmol) in DMF (10 mL) was added guanidine (0.14g, 2.4 mmol) at ambient temperature. The resulting solution was stirred at ambient temperature for 18 hr and diluted with ethyl









acetate and washed with brine. The organic layer was dried (MgSO_4) and concentrated. The residue was purified by reverse phase preparative HPLC to give title compound as a white powder. $(\text{M}+\text{H})^+ = 326$.









5









Examples 284 to 315



The following compounds were prepared employing a procedure analogous to that as set out in Example 283.


Examples	Structure	Characterization MS
284		$(\text{M}+\text{H})^+ 326$
285		$(\text{M}+\text{H})^+ 281$
286		$(\text{M}+\text{H})^+ 265$
287		$(\text{M}+\text{H})^+ 344$
288		$(\text{M}+\text{H})^+ 275$
289		$(\text{M}+\text{H})^+ 281$

290		(M+H) ⁺ 281
291		(M+H) ⁺ 351
292		(M+H) ⁺ 289
293		(M+H) ⁺ 386
294		(M+H) ⁺ 352
295		(M+H) ⁺ 387
296		(M+H) ⁺ 337
297		(M+H) ⁺ 372

298		(M+H) ⁺ 261
299		(M+H) ⁺ 261
300		(M+H) ⁺ 261
301		(M+H) ⁺ 283
302		(M+H) ⁺ 392
303		(M+H) ⁺ 359
304		(M+H) ⁺ 316
305		(M+H) ⁺ 378


306		(M+H) ⁺ 344
307		(M+H) ⁺ 406
308		(M+H) ⁺ 420
309		(M+H) ⁺ 391
310		(M+H) ⁺ 377
311		(M+H) ⁺ 409
312		(M+H) ⁺ 395
313		(M+H) ⁺ 362

314		(M+H) ⁺ 376
315		(M+H) ⁺ 300

Example 316


5

A.

2-Fluoro-4-bromo-N-phenylproline

To a solution of DL-proline (576 mg, 5 mmol) in 10/1 DMF-H₂O (7.5 ml) at RT were added CuI (48 mg, 0.25 mmol), Pd(PPh₃)₄ (290 mg, 0.25 mmol), K₂CO₃ (690 mg, 5 mmol), NEt₃ (1.4 ml, 10 mmol), triethylammonium bromide (158 mg, 0.75 mmol), and 1,4-dibromo-2-fluorobenzene. The resulting mixture was stirred in a sealed tube at 120°C for 48 hours. The reaction mixture was cooled to room temperature and poured onto saturated K₂CO₃/Et₂O. The aqueous layer was extracted 3X with Et₂O. The pH of the aqueous layer was adjusted to 4 and extracted 3X with EtOAc. The combined organics were washed with brine, dried over MgSO₄, and concentrated in vacuo to produce title compound which was used without further purification: LCMS (M+1) = 287.

B.











5 2-Fluoro-4-bromo-N-phenylproline acylguanidine









To a solution of Part A 2-fluoro-4-bromo-N-phenyl proline (215 mg, 0.75 mmol) in DMF (2.5 ml) at 25°C was added carbonyldiimidazole (147 mg, 0.9 mmol). The resulting solution was stirred 1 hour at 25°C. To the
 10 reaction mixture was added guanidine carbonate (300 mg, 1.5 mmol). The reaction mixture was stirred overnight at 25°C. The reaction mixture was poured onto H₂O/EtOAc. The aqueous layer was extracted 3X with EtOAc. The combined organics were washed 2X with brine, dried over Na₂SO₄, and
 15 concentrated in vacuo. Preparative HPLC provided 37 mg (15% over two steps) of a white solid: LCMS (M+) = 329.









Examples 317 to 347






The following compounds were prepared employing a
 20 procedure analogous to that as set out in Example 316.


Example No.	Structure	Characterization (MS)
317		(M+H) ⁺ 380
318		(M+H) ⁺ 405

319		(M+H) ⁺ 355
320		(M+H) ⁺ 454
321		(M+H) ⁺ 454
322		(M+H) ⁺ 329
323		(M+H) ⁺ 311
324		(M+H) ⁺ 267
325		(M+H) ⁺ 301
326		(M+H) ⁺ 278


327		(M+H) ⁺ 301
328		(M+H) ⁺ 285
329		(M+H) ⁺ 390
330		(M+H) ⁺ 318
331		(M+H) ⁺ 389
332		(M+H) ⁺ 267
333		(M+H) ⁺ 301
334		(M+H) ⁺ 269

335		(M+H) ⁺ 329
336		(M+H) ⁺ 269
337		(M+H) ⁺ 233
338		(M+H) ⁺ 247
339		(M+H) ⁺ 247
340		(M+H) ⁺ 247
341		(M+H) ⁺ 263
342		(M+H) ⁺ 269

343		(M+H) ⁺ 301
344		(M+H) ⁺ 275
345		(M+H) ⁺ 301
346		(M+H) ⁺ 249
347		(M+H) ⁺ 301


Example 348

A.



To a solution of 2,3-dimethylbenzoic acid (113 mg, 0.75 mmol) in DMF (1 ml) at 25°C was added PyBoP (367 mg, 0.83 mmol). The reaction mixture was shaken at 25°C for 20 minutes. To the reaction mixture was added resin-supported DL-proline ester (0.6mmol/g, 416 mg, 0.25 mmol). The resulting mixture was shaken overnight at 25°C. The resin was washed 3X each with CH₂Cl₂, MeOH, and DMF. Following a final wash with CH₂Cl₂, the resin was allowed to dry under vacuum. The resulting title compound was used without further purification.

B.















15


To a suspension of Part A compound (0.25 mmol) in DMF (2.5 ml) at 25°C was added guanidine (44 mg, 0.75 mmol). The reaction mixture was shaken overnight at 25°C. The resin beads were washed with CH₂Cl₂ (25 ml). The crude reaction mixture was filtered through a diatomaceous earth cartridge, eluting with CH₂Cl₂ (25 ml). The solvents were removed in vacuo. Purification of the crude residue via preparative HPLC (as described in Example 258 Step C) yielded 32 mg (44% over two steps) of a white solid: LCMS (M⁺) = 288.

Examples 349 to 360


The following compounds were prepared employing a procedure analogous to that set out in Example 348.

Example No.	Structure	Characterization (MS)
349		(M+H) ⁺ 261
350		(M+H) ⁺ 353
351		(M+H) ⁺ 289
352		(M+H) ⁺ 289
353		(M+H) ⁺ 289
354		(M+H) ⁺ 295
355		(M+H) ⁺ 295

356		(M+H) ⁺ 325
357		(M+H) ⁺ 311
358		(M+H) ⁺ 291
359		(M+H) ⁺ 311
360		(M+H) ⁺ 286

Example 361

A.




5

A solution of DL-Proline-OMe hydrochloride (100 mg, 0.6 mmol, 1.0 equiv.), TEA (253 μ l, 1.81 mmol, 3.0 equiv.), and p-chloro-benzyl bromide (123mg. 0.6 mmol, 1.0 equiv.)
 10 in dichloroethane (5 ml) was heated to 80°C for 20 min,

then RT for 3 hr. The solvent was removed under reduced pressure to give title compound which was used without purification in the next step.

5 B.











The crude Part A product mixture from G was redissolved in DMF (5 ml) and guanidine free base (100mg, excess) was added, and the reaction mixture was stirred for 10 18 hr. The solvent was removed under high vacuum and the crude product was purified by Prep-HPLC (as described in Example 258 Step C) to give the title acyl guanidine. Yield : 151 mg, 50%. LR-MS calcd 280, found (M+H)⁺ 281.

15 Examples 362 to 372


The following compounds were prepared employing a procedure analogous to that set out in Example 361.

Example No.	Structure	Characterization (MS)
362		(M+H) ⁺ 247
363		(M+H) ⁺ 281
364		(M+H) ⁺ 281

365		(M+H) ⁺ 279
366		(M+H) ⁺ 279
367		(M+H) ⁺ 318
368		(M+H) ⁺ 323
369		(M+H) ⁺ 318
370		(M+H) ⁺ 318
371		(M+H) ⁺ 318
372		(M+H) ⁺ 323

What is Claimed is:

1. A compound having the structure




- 5 wherein n is an integer from 1 to 5;

X is N or C-R⁵ wherein R⁵ is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl;


- R¹ is H, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, (alkyl or aryl)₃Si (where each
- 10 alkyl or aryl group is independent), cycloalkyl, cycloalkenyl, amino, alkylamino, alkenylamino, alkynylamino, arylalkylamino, aryl, arylalkyl, arylamino, aryloxy, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl, heteroarylamino, heteroaryloxy, arylthio,
- 15 arylsulfinyl, arylsulfonyl, thio, alkylthio, alkylsulfinyl, alkylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, halogen, haloalkyl, polyhaloalkyl, polyhaloalkoxy, aminothio, aminosulfinyl, aminosulfonyl, alkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonyl-
- 20 amino, arylsulfonylamino, heteroarylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, hydroxy, acyl, carboxy, aminocarbonyl, alkylcarbonyl, alkoxy carbonyl, alkylcarbonyloxy, alkylcarbonylamino, arylcarbonyl, arylcarbonyloxy,
- 25 arylcarbonylamino, heteroarylcarbonyl, heteroarylcarbonyloxy, heteroarylcarbonylamino, cyano, nitro, alkenylcarbonylamino, alkynylcarbonylamino, alkylaminocarbonylamino, alkenylaminocarbonylamino, alkynylaminocarbonylamino, arylaminocarbonylamino,
- 30 heteroarylaminocarbonylamino, alkoxy carbonylamino, alkenyloxy carbonylamino, alkynyloxy carbonylamino, aryloxy carbonylamino, heteroaryloxy carbonylamino, aminocarbonylamino, alkylaminocarbonyloxy, alkoxy carbonyl-amino; 1,1-(alkoxy or aryloxy)₂alkyl (where the two aryl

or alkyl substituents can be independently defined, or linked to one another to form a ring), $S(O)_2R^6R^7$, $-NR^6(C=NR^7)alkyl$, $-NR^6(C=NR^7)alkenyl$, $-NR^6(C=NR^7)alkynyl$,



-NR⁶(C=NR⁷)heteroaryl, -NR⁸(C=NCN)-amino,

5 pyridine-N-oxide,



H₂ and n' is 0, 1, 2 or 3) or $\text{NR}^8\text{R}^9 \overset{\text{O}}{\parallel} \text{C}=\text{CH}-\text{C}-\text{R}^8$; tetrazolyl, imidazole, oxazole or triazole, $-\text{PO}(\text{R}^{13})(\text{R}^{14})$, (where R¹³ and R¹⁴ are independently alkyl, aryl, alkoxy, aryloxy,

10 heteroaryl, heteroarylalkyl, heteroaryloxy,
heteroarylalkoxy, cycloheteroalkyl, cycloheteroalkylalkyl,
cycloheteroalkoxy, or cycloheteroalkylalkoxy);

R⁶, R⁷, R⁸ and R⁹ are independently hydrogen, alkyl, haloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl or

15 (cycloalkyl)alkyl, or cycloheteroalkyl;

and R¹ may be optionally substituted with from one to five substituents

R², R³ and R⁴ are the same or different and are independently any of the groups set out for R¹ and may be optionally substituted with from one to five substituents; including pharmaceutically acceptable salts thereof, prodrug esters thereof, and all stereoisomers thereof.


2. The compound as defined in Claim 1 wherein at least one of R¹, R², R³ and R⁴ is aryl or heteroaryl.

25 3. The compound as defined in Claim 1 wherein X is
N.


4. The compound as defined in Claim 1 wherein X is C-R⁵.

5. The compound as defined in Claim 1 wherein R¹ is
30 aryl or heteroaryl.

6. The compound as defined in Claim 1 having the formula




7. The compound as defined in Claim 1 having the formula




8. The compound as defined in Claim 6 wherein R¹ is aryl or heteroaryl.

9. The compound as defined in Claim 1 wherein the moiety



is



10


10. The compound as defined in Claim 1 wherein R² and R³ are independently H, lower alkyl, lower alkoxy or aryl, and R⁴ and R⁵ are each hydrogen.

11. The compound as defined in Claim 1 wherein n is 1.

12. The compound as defined in Claim 1 wherein n is 1, R² and R³ are independently H or lower alkyl, and R⁴ and R⁵ are each H, and R¹ is aryl or heteroaryl.


13. The compound as defined in Claim 1 wherein R¹ is phenyl, substituted phenyl or heteroaryl.

14. The compound as defined in Claim 1 wherein R¹ is phenyl, halophenyl, dihalophenyl, alkylphenyl, nitrophenyl, dialkoxyphenyl, trifluoromethylphenyl, biphenyl, heteroarylphenyl, cycloheteroalkylphenyl, alkylthiophenyl, trialkoxyphenyl or halo(dialkoxy)phenyl, phenylalkyl,




15. The compound as defined in Claim 1 wherein R^1 , R^2 , R^3 and/or R^4 may be joined together with the N atom and/or carbons to which they are attached to form a non-aromatic ring.


16. The compounds as defined in Claim 6 wherein



is



17. The compound as defined in Claim 7 wherein




15


18. The compound as defined in Claim 1 wherein R^1 is phenyl, 4-bromophenyl, 4-chlorophenyl, 3-bromophenyl, 3,5-dimethoxyphenyl, 4-methylphenyl, 2,4-dichlorophenyl, 3-nitrophenyl, 2-chlorophenyl, 3-chlorophenyl, 2,5-dimethylphenyl, 2-methylphenyl, 3-methylphenyl, 4-

20


- methylphenyl, 2,3-dimethoxy phenyl, 4-trifluoromethyl-
 phenyl, 3-trifluoromethoxyphenyl, 4-biphenyl, 2-bromo-4,5-
 dimethoxyphenyl, 4-methylthiophenyl, 3,4,5-trimethoxy-
 phenyl, 4-fluorophenyl, 2-chloro-3,4-dimethoxyphenyl, 4-
 5 nitrophenyl, benzyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-
 methoxyphenyl, 3-bromo-4-fluorophenyl, 3-ethoxyphenyl, 3-
 trifluoromethylphenyl, 3,5-difluorophenyl, 3,5-dichloro-
 phenyl, 3,5-ditrifluoromethylphenyl, 3-trifluorophenyl, 3-
 (N-pyrrolyl)phenyl, 3-(N-pyrrolidinyl)phenyl, 3-(N-
 10 pyrazolinyl)phenyl, 3-(N-imidazolyl)phenyl,



- 15 where R_1 and R_2 are independently H or Cl,




where R_3 is NH_2 , CH_3 , CF_3 and R_4 and R_5 are independently H, 2-F, 2,5-diF, 2- CF_3 , 3- CF_3 ,



5

where R_6 , R_7 and R_8 are independently H, 2- NO_2 , 2- CF_3 ,




3- CF_3 , 3-CN-, 5- CF_3 , 4- NO_2 , 4-O=CH-, 2- CH_3O -, 3- CH_3O -, 4- CH_3O -, 5- CH_3O -, 6- CH_3O -, 3-OH, 4-(CH_3) $_2\text{N}$ -, 4-OH, 2-F, 3-F, 4-F, 5-F, 6-F, 4-isopropyl, 2-Br, 5-Br, 3-Br, 10 4- CH_3SO_2 , 4-benzyloxy, 3- CH_3CH_2 -, 2- CH_3 -, 3- CH_3 -, 6- CH_3 -, 4-t-butyl, 4- $\text{CH}_3\text{CH}_2\text{O}$ - 4-cyclohexyl, 4-phenoxy, 4- $\text{CH}_3\text{-SO}_2\text{-NH}$ -,
4-isopropyl-C(=O)-NH.

19. The compound as defined in Claim 1 wherein n is 1, X is CH, R^2 and R^3 are independently lower alkyl, and R^1 is dihydrobenzofuran.

15


20. The compound as defined in Claim 1 having the formula




20




5

10









5





10








5




10







5

















21. The compound as defined in Claim 1 having the
10 formula





22. The compound as defined in Claim 1 having the
formula




5








5






23. The compound as defined in Claim 1 having the
10 formula



24. The compound as defined in Claim 1 wherein the moiety



25. A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

26. A method for preventing or treating disorders caused by intracellular acidosis during myocardial ischemia, hypertension, angina pectoris, cardiac arrhythmia, reperfusion injury, myocardial necrosis, cardiac dysfunction, LDL-cholesterol, renal disease or heart failure, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

27. A method for preventing or treating myocardial ischemia, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/25829

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,336,689 A (WEBER et al) 09 August 1994, col. 5, lines 26-59.	1-25
Y	EP 0 639 573 A1 (HOECHST AKTIENGESELLSCHAFT) 22 February 1995, page 5, lines 35-55.	1-27
Y	EP 0 803 501 A1 (SUMITOMO PHARMACEUTICALS COMPANY, LIMITED) 29 October 1997, Abstract; page 42, lines 35-58; page 43, lines 1-58; page 44, lines 1-54.	1-27
Y	EP 0 738 712 A1 (HOECHST AKTIENGESELLSCHAFT) 23 October 1996, Abstract; page 2, lines 1-54.	1-27

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 FEBRUARY 1999

Date of mailing of the international search report

25 MAR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JANE C. OSWECKI

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/25829

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)*

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US98/25829**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (6):

A61K 31/33, 31/34, 31/36, 31/38, 31/40, 31/41, 31/42, 31/44, 31/55, 31/155, 31/165, 31/335, 31/395, 31/415, 31/435, 31/445; C07C 279/02, 279/16, 279/18, 279/20, 279/24; C07D 203/10, 203/12, 203/14, 205/04, 207/04, 207/08, 207/09, 211/08, 211/10, 211/12, 211/14, 211/16, 211/18, 211/22, 211/26, 211/38, 211/40, 211/80, 211/82, 213/06, 213/26, 213/28, 213/30, 213/36, 213/46, 213/50, 213/53, 213/56, 213/58, 223/04, 223/08, 223/10, 231/12, 231/38, 233/60, 233/61, 271/04, 271/12, 307/78, 307/87, 307/93, 311/20, 317/44, 333/20, 333/22, 405/10, 409/10, 498/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/183, 210, 212, 277, 317, 330, 331, 364, 385, 396, 403, 406, 423, 427, 428, 429, 438, 451, 461, 464, 467, 613, 617, 624, 634; 540/529, 531; 546/192, 225, 231, 314, 316, 323, 329, 336, 337, 339, 340; 548/131, 143, 300.1, 335.1, 342.5, 343.1, 343.5, 356.1, 371.1, 537, 561, 562, 564, 579, 953, 954; 549/70, 72, 74, 75, 396, 430, 441, 442, 444, 448, 452, 454, 469; 564/189, 190, 191, 230, 237

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/183, 210, 212, 277, 317, 330, 331, 364, 385, 396, 403, 406, 423, 427, 428, 429, 438, 451, 461, 464, 467, 613, 617, 624, 634; 540/529, 531; 546/192, 225, 231, 314, 316, 323, 329, 336, 337, 339, 340; 548/131, 143, 300.1, 335.1, 342.5, 343.1, 343.5, 356.1, 371.1, 537, 561, 562, 564, 579, 953, 954; 549/70, 72, 74, 75, 396, 430, 441, 442, 444, 448, 452, 454, 469; 564/189, 190, 191, 230, 237

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE

search terms: guanid?, acyl, cyclopropan?, cyclobutan?, cyclopentan?, cyclohexan?, cycloheptan?, aziridin?, azetidin?, pyrrolidin?, piperidin?, azepin?, (sodium or Na) (L) (block or inhibit?)

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim 1, drawn to compounds of the formula depicted in claim 1 having a non-bridged carbocyclic ring with no heterocyclic substituents attached.

Group II, claim 1, drawn to compounds of the formula depicted in claim 1 having bridged carbocyclic ring.

Group III, claim 1, drawn to compounds of the formula depicted in claim 1 having a carbocyclic ring and benzodioxane as R¹.

Group IV, claim 1, drawn to compounds of the formula depicted in claim 1 having a carbocyclic ring and either 1,2,3- or 1,2,4-benzoxadiazole as R¹.

Group V, claim 1, drawn to compounds of the formula depicted in claim 1 having pyrrole or pyrrolidine as a heterocyclic ring.

Group VI, claim 1, drawn to compounds of the formula depicted in claim 1 having a carbocyclic ring with 1,2-diazole or pyrazole as R¹.

Group VII, claim 1, drawn to compounds of the formula depicted in claim 1 having a carbocyclic ring with 1,3-diazole or imidazole as R¹.

Group VIII, claim 1, drawn to compounds of the formula depicted in claim 1 having pyridine or piperidine as a heterocyclic ring.

Group IX, claim 1, drawn to compounds of the formula depicted in claim 1 having a carbocyclic ring and pyrazole and/or dioxolane as R¹.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/25829

Group X, claim 1, drawn to compounds of the formula depicted in claim 1 having a carbocyclic ring and benzofuran as R¹.

Group XI, claim 1, drawn to compounds of the formula depicted in claim 1 having a carbocyclic ring and benzopyran as R¹.

Claims 2-27 will be examined as commensurate in scope with the group(s) elected.

The inventions listed as Groups I-XI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: no special technical feature which makes a contribution over the prior art exists within the claimed compounds depicted in the formula in claim 1. All compounds of the formula shown comprise the known amino acid guanidine and known heterocyclic, bridged carbocyclic and/or carbocyclic substituent moieties. Any contribution over the prior art must, therefore, reside in the possibilities for the various substituents and combinations thereof, which render the compounds different from one another; as such, they are not known as equivalents in the art.